Ben Johnson

  • ‘Human Microbiome Market: Focus on Therapeutics (including gut-brain axis targeting drugs

    Key Inclusions

    • A detailed assessment of the current market landscape of microbiome therapeutics, providing information on drug / therapy developer(s) (such as year of establishment, location of headquarters and company size), clinical study sponsor(s) or collaborators, phase of development (clinical, preclinical, and discovery stage) of product candidates, type of molecule (small molecule and biologic), type of therapy (prebiotic, probiotic, and prescription drug), target indication(s), key therapeutic area(s), molecular / biological target (if available), mechanism of action (if available), route of administration, type of drug formulation (tablet, capsule, gel, lotion, cream, ointment, nasal spray and 4+ categories), dosing frequency (reported for clinical candidates only), and information on special drug designations (if any). In addition, the chapter highlights the various technology platforms that are being actively used for the development of microbiome therapeutics.

     

    • Elaborate profiles of key players (established after 2005) that are engaged in the development of microbiome therapeutics (which are presently in both preclinical and clinical stages of development); each profile features a brief overview of the company, its financial information (if available), microbiome-based product portfolio, information on advanced stage (phase II and above) pipeline candidates (featuring a drug overview, current status of development, clinical trial information, and clinical trial end-point analysis) and an informed future outlook.

     

    • A discussion on the various types of diagnostic tests, specifically highlighting the importance of next-generation sequencing within this field of research, along with [A] a detailed review of the current market landscape of microbiome diagnostic tests, including the information on the developer(s) (such as year of establishment, location of headquarters and company size), stage of development (commercialized and under development), type of sample used (blood, feces, saliva and vaginal swab), target indication(s), key therapeutic area(s), result turnaround time, and purpose of diagnosis, [B] brief profiles of popular diagnostic developers, and [C] an indicative list of screening and profiling test kits, including information on the developer(s) (such as year of establishment, location of headquarters and company size), type of sample used (blood, feces, saliva and vaginal swab), key therapeutic area(s), and result turnaround time.

     

    • A review of the historical evolution and other relevant aspects of FMT therapies, including details on the process of donor selection, therapy procedure, route of administration, important clinical guidelines, regulatory guidelines and insurance coverage, along with [A] a detailed assessment of the current market landscape of FMT therapies, providing information on FMT developer(s) (such as year of establishment, location of headquarters and company size), status of development (commercialized, clinical, and preclinical stage), target indication(s), key therapeutic area(s), and route of administration, [B] a geographical clinical trial analysis of ongoing / planned / completed studies of FMTs sponsored by non-industry players, featuring details related to specific FMT therapies and analysis based on relevant parameters, such as the number of registered trials, year of registration, current status, phase of development, study design, type of sponsor(s), target indication(s), key therapeutic area(s), key focus areas, number of patients enrolled and leading non-industry player(s), and [C] information on various stool banks (including year of establishment and location of headquarters), along with brief profiles of the most prominent stool banks located across the globe.

     

    • A detailed business portfolio analysis based on an attractiveness and competitiveness (AC) framework, highlighting the current market attractiveness and existing competition across the most popular disease indication(s) for which microbiome therapeutics are under investigation.

     

    • An analysis of the varied microbiome-focused initiatives of big pharma players (out of top 20 established pharmaceutical players), featuring a [A] heat map representation that highlights microbiome therapeutics under development (in partnership with core microbiome product developers), along with information on funding, partnership activity, and diversity of product portfolio (in terms of disease indication(s) being treated and focus therapeutic area(s)), and [B] a spider web representation of the individual competitiveness of the initiatives of big pharma players based on multiple relevant parameters.

     

    • An analysis of the start-ups / small-sized players (established in the last seven years, with less than 50 employees) engaged in the development of microbiome therapeutics and diagnostics, featuring heat map representation based on parameters, such as number of microbiome therapeutics under development, diversity of product portfolio, funding information (including funding amount, number of investors and evolution of investment activity), partnership activity, disease indication(s) being treated and focus therapeutic area(s), and strength of intellectual property portfolio.

     

    • An assessment of the most commonly targeted therapeutic indications and details of microbiome-based drugs that are being developed against them, highlighting key epidemiological facts about specific diseases, available methods of diagnosis, and currently available treatment options and their side effects.

     

    • An analysis of the investments made, including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings, at various stages of development in start-ups / small-sized companies (established in last seven years, with less than 50 employees) that are focused on developing microbiome therapeutics and diagnostics.

     

    • An elaborate discussion on the various steps involved in the development and manufacturing of microbiome therapeutics, along with [A] an indicative list of contract manufacturers, along with details on year of establishment, location of headquarters, company size, scale of operation, facility location and microbiome production capacity, [B] an indicative list of companies with in-house manufacturing facilities for microbiome therapeutics, along with details on year of establishment, location of headquarters, and company size, [C] an indicative list of CROs that currently claim to have the necessary capabilities to offer various research services (such as screening, sequencing, characterization, analytical), along with details on year of establishment, location of headquarters, company size, and service portfolio details, and [D] an insightful Harvey ball analysis of key considerations that need to be taken into account by industry stakeholders while selecting a suitable CMO / CRO partner.

     

    • An assessment of the emerging role of big data, highlighting efforts focused on the development and implementation of various algorithms / tools to analyze data generated from microbiome research along with [A] an insightful google trends analysis to demonstrate the rising interest of stakeholders in using big data tools to support microbiome research over the past decade, [B] a list of companies offering big data-related services / tools to support microbiome research, and [C] brief profiles of some of the popular companies that are engaged in this field of research.

     

    • An informative case study on the various other applications of microbiome products, such as agriculture, animal health, plant health, food products, featuring a list of nearly 80 products, including probiotic supplements, cosmetics, and over-the-counter (OTC) products that are being used as dietary supplements.

     

    The USD 4 billion (by 2030) financial opportunity within the microbiome therapeutics (Tx) market and diagnostics (Dx) markets, has been analyzed across the following segments:

    • Type of Therapy (Tx)
    • Prescription Drug
    • Prebiotics
    • Probiotics

     

    • Type of Molecule (Tx)
    • Small Molecules
    • Biologics

     

    • Target Indication (Tx+Dx)
    • Acne Vulgaris
    • Atopic Dermatitis
    • Clostridium difficile Infection
    • Colorectal Cancer
    • Crohn’s Disease
    • Diabetes
    • Irritable Bowel Syndrome
    • Lactose Intolerance
    • Lung Cancer
    • Nonalcoholic steatohepatitis (NASH)
    • Obesity
    • Ulcerative colitis

     

    • Therapeutic Area (Tx+Dx)
    • Autoimmune Disorders
    • Dental Disorders
    • Digestive and Gastrointestinal Disorders
    • Dermatological Disorders
    • Infectious Disease
    • Metabolic Disorders
    • Oncology
    • Others

     

    • Key Geographical Regions (Tx+Dx)
    • North America
    • Europe
    • Asia-Pacific and Rest of the World

     

    To request sample pages, please visit this link

     

    Key Questions Answered

    • Who are the leading developers of microbiome therapeutics and diagnostic tests?
    • What are the key technology platforms (available / under development) for microbiome-related therapies and diagnostics?
    • What are the disease indications against which microbiome-based therapeutics are being evaluated?
    • Which companies are targeting gut-brain axis for the development of microbiome therapies?
    • Who are the leading (industry and non-industry) players involved in the development of FMT products?
    • Who are the key contract research / manufacturing service providers in this domain?
    • What is the trend in capital investments in microbiome-related R&D?
    • What are the contributions of big pharma players in this domain?
    • Which are the popular players offering big data-related services / tools to support microbiome research?
    • How is the current and future market opportunity for microbiome-based therapeutics and diagnostics is likely to be distributed across key market segments?

     

    You may also be interested in the following titles:

    1. Antibody Drug Conjugates Market (5th Edition), 2019-2030
    2. Gene Therapy Market (3rd Edition), 2019 - 2030
    3. Global T-Cell (CAR-T, TCR, and TIL) Therapy Market (4th Edition), 2019 – 2030
    4. Synthetic Lethality-based Drugs and Targets Market, 2019-2030

     

    Contact:

    Gaurav Chaudhary

    +1 (415) 800 3415

    Gaurav.Chaudhary@rootsanalysis.com


  • Presently, 260 drug candidates are being evaluated in clinical / preclinical stages

    The concept of microbiome-based therapeutics has generated significant enthusiasm within the medical science community, defining a new frontier in the field of medicine. Despite having captured the interest of several venture capital firms and big pharma players, no microbiome-based therapeutic has been officially approved by an authorized medical product regulator. However, the current development pipeline of microbiome therapeutics has several promising candidates that are likely to result in commercial success stories soon.

     

    To order this 640+ page report, which features 235+ figures and 275+ tables, please visit this link

     

    The USD 4 billion (by 2030) financial opportunity within the microbiome therapeutics (Tx) market and diagnostics (Dx) markets, has been analyzed across the following segments:

    • Type of Therapy (Tx)
    • Prescription Drug
    • Prebiotics
    • Probiotics

     

    • Type of Molecule (Tx)
    • Small Molecules
    • Biologics

     

    • Target Indication (Tx+Dx)
    • Acne Vulgaris
    • Atopic Dermatitis
    • Clostridium difficile Infection
    • Colorectal Cancer
    • Crohn’s Disease
    • Diabetes
    • Irritable Bowel Syndrome
    • Lactose Intolerance
    • Lung Cancer
    • Nonalcoholic steatohepatitis (NASH)
    • Obesity
    • Ulcerative colitis

     

    • Therapeutic Area (Tx+Dx)
    • Autoimmune Disorders
    • Dental Disorders
    • Digestive and Gastrointestinal Disorders
    • Dermatological Disorders
    • Infectious Disease
    • Metabolic Disorders
    • Oncology
    • Others

     

    • Key Geographical Regions (Tx+Dx)
    • North America
    • Europe
    • Asia-Pacific and Rest of the World

     

     

    The Human Microbiome Market, 2019-2030 report features the following companies, which we identified to be key players in this domain:

    • 4D Pharma
    • Armata Pharmaceuticals
    • Evelo Biosciences
    • Rebiotix (Acquired by Ferring Pharmaceuticals)
    • Seres Therapeutics
    • Vedanta Biosciences

     

    Table of Contents

    1. Preface

     

    1. Executive Summary

     

    1. Introduction

     

    1. Microbiome Therapeutics: Market Landscape

     

    1. Company and Drug Profiles

     

    1. Microbiome Diagnostics: Market Landscape

     

    1. Fecal Microbiota Therapy (FMT)

     

    1. Attractiveness Competitiveness (AC) Matrix

     

    1. Microbiome Related Initiatives of Big Pharmaceutical Players

     

    1. Start-up Health Indexing

     

    1. Key Therapeutics Areas

     

    1. Funding and Investment Analysis

     

    1. Contract Services for Microbiome Therapeutics

     

    1. Big Data and Microbiome Therapeutics

     

    1. Microbiome Therapeutics: Market Forecast and Opportunity Analysis

     

    1. Microbiome Diagnostics: Market Forecast and Opportunity Analysis

     

    1. Fecal Microbiota Therapies: Market Forecast and Opportunity Analysis

     

    1. Case Study: Microbiome-based Products in Other Industries

     

    1. Concluding Remarks

     

    1. Executive Insights

     

    1. Appendix I: Tabulated Data

     

    1. Appendix II: List of Companies and Organizations

     

     

    To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/human-microbiome-market/281.html

     

    Contact Details

    Gaurav Chaudhary

    +1 (415) 800 3415

    gaurav.chaudhary@rootsanalysis.com 


  • Human Microbiome-based Products Market is projected to be worth USD 4 Billion by 2030

    Roots Analysis has announced the addition of “Human Microbiome Market, 2019-2030” report to its list of offerings.

     

    To order this 640+ page report, which features 235+ figures and 275+ tables, please visit this link

     

    Key Market Insights

    • Presently, 260 drug candidates are being evaluated in clinical / preclinical stages for the treatment of a wide variety of disease indications; the US has emerged as the major hub for microbiome-based research
    • The pipeline features both prebiotic and probiotic drugs, being evaluated across different stages of development; majority of these products are designed for administration via non-invasive routes, such as oral and topical
    • Microbiome therapeutics have demonstrated the potential to target a range of therapeutic areas; digestive and GI disorders, oncology, infectious diseases, and metabolic disorders are amongst the prime focus areas
    • Over 10 microbiome-focused disease diagnosis tests are already available in the market; several companies claim to have initiatives in this domain based on different sample types and therapeutic areas
    • Presently, FMTs are the only commercially available microbiome products for the treatment of recurrent CDIs; in fact, several trials evaluating FMTs, sponsored by non-industry players, have been registered in the past decade
    • Over time, well funded start-ups have initiated product development programs, having invested significant time and effort to explore the applicability of microbiome therapeutics across various indications
    • Several big pharmaceutical players have partnered with smaller and dedicated microbiome-based therapy / diagnostic developers in order to expand their respective capabilities in this upcoming field of pharmacology
    • Contract service providers have become an integral part of microbiome supply chain owing to their technical expertise and ability to overcome existing challenges related to both R&D and production
    • Prevalent trends indicate that microbiome drugs and diagnostics market is poised to grow significantly; the forecasted opportunity is anticipated to be distributed across different target indications and regions
    • Microbiome therapeutic developers are expected to witness significant momentum, in terms of revenues generation, as multiple late stage molecules for the treatment of different clinical conditions get commercialized

     

    For more information please visit: 

    https://www.rootsanalysis.com/reports/view_document/human-microbiome-market/281.html

     

    Table of Contents

    1. PREFACE

    1.1.       Scope of the Report

    1.2.       Research Methodology

    1.3.       Chapter Outlines

     

    1. EXECUTIVE SUMMARY

     

    1. INTRODUCTION

    3.1.       Chapter Overview

    3.2.       Concept of Microbiota and Microbiome

    3.2.1.    Discovery of the Human Microbiome

    3.2.2.    Functions of the Human Microbiome

     

    3.3.       Overview of Gut Flora

    3.3.1.    Role of Gut Flora in Healthy Individuals

    3.3.2.    Factors Affecting Gut Flora

    3.3.2.1. Antibiotic Consumption

    3.3.2.2. Age and Pregnancy

    3.3.2.2.1. Mode of Childbirth

    3.3.2.2.2. Type of Feeding

    3.3.2.2.3. Antibiotic Consumption by Mother

    3.3.2.3. Stress-related Factors

    3.3.2.4. Dietary Factors

    3.3.2.5. Impact of Lifestyle

     

    3.4.       The Microbiome and Disease

    3.4.1.    Cancer

    3.4.2.    Inflammatory Bowel Disease (IBD)

    3.4.3.    Obesity

    3.4.4.    Parkinson’s Disease

    3.4.5.    Type-II Diabetes

    3.4.6.    Other Disease Indications

    3.5.       Impact of Microbiota on Drug Pharmacokinetics

    3.6.       Impact of Microbiota on Therapeutic Outcomes

     

    3.7.       Microbiome Therapeutics

    3.7.1.    Probiotics

    3.7.1.1. Beneficial Bacterial Strains

    3.7.1.1.1. Lactobacilli

    3.7.1.1.2. Bifidobacteria

    3.7.1.1.3. Others

     

    3.7.1.2. Key Therapeutic Areas

    3.7.1.2.1. Antibiotic-Associated Diarrhea (AAD)

    3.7.1.2.2. Bacterial Vaginosis

    3.7.1.2.3. High Blood Pressure

    3.7.1.2.4. Hypercholesterolemia

    3.7.1.2.5. Infectious Childhood Diarrhea (ICD)

    3.7.1.2.6. Inflammatory Bowel Disease (IBD)

    3.7.1.2.7. Lactose Intolerance

    3.7.1.2.8. Vitamin Production

    3.7.1.2.9. Weight Management

     

    3.7.1.3. Side Effects of Probiotics

     

    3.7.2.    Prebiotics

    3.7.2.1. Sources of Prebiotics

    3.7.2.2. Types of Prebiotics

    3.7.2.2.1. Fructo-Oligosaccharides (FOS)

    3.7.2.2.2. Galacto-Oligosaccharides (GOS)

    3.7.2.2.3. Inulin

     

    3.7.2.3. Key Therapeutic Areas

    3.7.2.3.1. Antibiotic Associated Diarrhea (AAD)

    3.7.2.3.2. Constipation

    3.7.2.3.3. Gastrointestinal Disorders

    3.7.2.3.4. Dysbiosis

    3.7.2.4. Side Effects of Prebiotics

     

    3.8.       The Human Microbiome Project (HMP)

    3.8.1.    Project Approach

    3.8.2.    Project Initiatives

    3.8.3.    Project Achievements

                           

    3.9.       Regulatory Guidelines for Live Biotherapeutic Products (LBPs)

    3.10.     Key Challenges in the Development of Microbiome Therapeutics

    3.11.     Future Perspectives

     

    1. MICROBIOME THERAPEUTICS: MARKET LANDSCAPE

    4.1.       Chapter Overview

    4.2.       Microbiome Therapeutics: Clinical Pipeline

    4.2.1.    Analysis by Phase of Development

    4.2.2.    Analysis by Type of Molecule

    4.2.3.    Analysis by Type of Therapy

    4.2.4.    Analysis by Target Indication

    4.2.5.    Analysis by Therapeutic Area

    4.2.6.    Analysis by Dosing Frequency

    4.2.7.    Analysis by Route of Administration

    4.2.8.    Analysis by Drug Formulation

     

    4.3.       Microbiome Therapeutics: Early-Stage Pipeline

    4.3.1.    Analysis by Phase of Development

    4.3.2.    Analysis by Type of Molecule

    4.3.3.    Analysis by Type of Therapy

    4.3.4.    Analysis by Target Indication

    4.3.5.    Analysis by Therapeutic Area

     

    4.4.       Microbiome Therapeutics: List of Drug Developers

    4.4.1.    Analysis by Year of Establishment

    4.4.2.    Analysis by Location of Headquarters

    4.4.3.    Analysis by Company Size

    4.4.4.    Analysis by Company Size and Location of Headquarters

    4.4.5.    Leading Drug Developers: Analysis by Number of Microbiome Therapeutics

     

    4.5.       Grid Analysis: Microbiome and Key Therapeutic Areas

     

    4.6.       Microbiome Therapeutics: List of Discontinued Drugs

    4.7.       Emerging Role of Microbiome in Gut-Brain Axis

    4.8.       Microbiome Therapeutics: List of Technology Platforms

     

    1. COMPANY AND DRUG PROFILES

    5.1.       Chapter Overview

    5.2.       4D Pharma

    5.2.1.    Company Overview

    5.2.2.    Microbiome-based Product Portfolio

    5.2.2.1. Blautix®

    5.2.2.1.1. Drug Overview

    5.2.2.1.2. Current Status of Development

    5.2.2.1.3. Clinical Studies

    5.2.2.1.4. Clinical Trial End-Point Analysis

    5.2.3.    Recent Developments and Future Outlook

     

    5.3.       Armata Pharmaceuticals

    5.3.1.    Company Overview

    5.3.2.    Microbiome-Based Product Portfolio

    5.3.2.1. C16G2

    5.3.2.1.1. Drug Overview

    5.3.2.1.2. Current Status of Development

    5.3.2.1.3. Clinical Studies

    5.3.2.1.4. Clinical Trial End-Point Analysis

    5.3.3.    Recent Developments and Future Outlook

     

    5.4.       Evelo Biosciences

    5.4.1.    Company Overview

    5.4.2.    Microbiome-Based Product Portfolio

    5.4.2.1. EDP1503

    5.4.2.1.1. Drug Overview

    5.4.2.1.2. Current Status of Development

    5.4.2.1.3. Clinical Studies

    5.4.2.1.4. Clinical Trial End-Point Analysis

    5.4.3.    Recent Developments and Future Outlook

     

    5.5.       Rebiotix (Acquired by Ferring Pharmaceuticals)

    5.5.1.    Company Overview

    5.5.2.    Financial Information

    5.5.3.    Microbiome-Based Product Portfolio

    5.5.3.1. RBX2660

    5.5.3.1.1. Drug Overview

    5.5.3.1.2. Current Status of Development

    5.5.3.1.3. Clinical Studies

    5.5.3.1.4. Clinical Trial End-Point Analysis

    5.5.4.    Recent Developments and Future Outlook

     

    5.6.       Seres Therapeutics

    5.6.1.    Company Overview

    5.6.2.    Financial Information

    5.6.3.    Microbiome-Based Product Portfolio

    5.6.3.1. SER-109

    5.6.3.1.1. Drug Overview

    5.6.3.1.2. Current Status of Development

    5.6.3.1.3. Clinical Studies

    5.6.3.1.4. Clinical Trial End-Point Analysis

     

    5.6.3.2. SER-287

    5.6.3.2.1. Current Status of Development

    5.6.3.2.3. Clinical Studies

    5.6.3.2.4. Clinical Trial End-Point Analysis

    5.6.4.    Recent Developments and Future Outlook

     

    5.7.       Vedanta Biosciences

    5.7.1.    Company Overview

    5.7.2.    Microbiome-Based Product Portfolio

    5.7.2.1. VE303

    5.7.2.1.1. Drug Overview

    5.7.2.1.2. Current Status of Development

    5.7.2.1.3. Clinical Studies

    5.7.3.1.4. Clinical Trial End-Point Analysis

    5.7.3.    Recent Developments and Future Outlook

     

    1. MICROBIOME DIAGNOSTICS: MARKET LANDSCAPE

    6.1.       Chapter Overview

    6.2.       Overview of Microbiome Diagnostic Tests

    6.3.       Microbiome Diagnostic Tests: Marketed and Under Development Products

    6.3.1.    Analysis by Stage of Development

    6.3.2.    Analysis by Type of Sample Required

    6.3.3.    Analysis by Target Indication

    6.3.4.    Analysis by Therapeutic Area

    6.3.5.    Analysis by Purpose

     

    6.4.       Microbiome Diagnostic Tests: List of Diagnostic Developers

    6.4.1.    Analysis by Year of Establishment

    6.4.2.                Analysis by Location of Headquarters

    6.4.3.    Analysis by Company Size

    6.4.4.    Analysis by Company Size and Location of Headquarters

    6.4.5.    Leading Diagnostic Developers: Analysis by Number of Microbiome Diagnostics

     

    6.5.       Profiles of Prominent Diagnostic Developers

    6.5.1.    Enterome Bioscience

    6.5.1.1. Company Overview

    6.5.1.2. Service Portfolio

     

    6.5.2.    Vaiomer

    6.5.2.1. Company Overview

    6.5.2.2. Service Portfolio

    6.6.       Overview of Microbiome Screening / Profiling Tests

    6.6.1.    List of Microbiome Screening / Profiling Tests

    6.6.2.    List of Microbiome Screening / Profiling Test Developers

     

    1. FECAL MICROBIOTA THERAPY (FMT)

    7.1.       Chapter Overview

    7.2.       Introduction to FMT

    7.3.       Historical Overview

    7.4.       FMT: Procedure and Clinical Relevance

    7.4.1.    Donor Selection

    7.4.2.    Administration Procedure

    7.4.3.    Routes of Administration

    7.4.4.    Consequences and Adverse Events

    7.4.5.    Clinical Guidelines Associated with FMT

     

    7.5.       Regulatory Guidelines Related to FMT

    7.6.       Insurance Coverage for FMT

     

    7.7.       FMT: Competitive Landscape

    7.7.1.    Marketed / Development Pipeline (Industry Players)

    7.7.1.1. Analysis by Phase of Development

    7.7.1.2. Analysis by Therapeutic Area

    7.7.1.3. Analysis by Route of Administration

     

    7.7.2.    List of Developers (Industry Players)

    7.7.2.1. Analysis by Year of Establishment

    7.7.2.2. Analysis by Location of Headquarters

    7.7.2.3. Analysis by Company Size

     

    7.8.       Clinical Trial Analysis (Non-Industry Sponsored)

    7.8.1.    Scope and Methodology

    7.8.2.    List of Clinical Trials

    7.8.2.1. Analysis by Trial Registration Year

    7.8.2.2. Analysis by Trial Status

    7.8.2.3. Analysis by Phase of Development

    7.8.2.4. Analysis by Patients Enrolled

    7.8.2.5. Analysis of Number of Patients Enrolled by Trial Registration Year

    7.8.2.6. Analysis by Therapeutic Area

    7.8.2.7. Analysis by Popular Target Indications

    7.8.2.8. Analysis by Trial Registration Year and Recruitment Status

    7.8.2.9. Analysis by Study Design

    7.8.2.10.           Leading Non-Industry Players: Analysis by Number of Trials

    7.8.2.11.           Geographical Analysis by Number of Clinical Trials

    7.8.2.12.           Geographical Analysis by Enrolled Patient Population

    7.8.2.13.           Analysis by Type of Sponsor / Collaborator

    7.8.2.14.           Analysis by Trial Focus

    7.8.2.15.           Key Clinical Trials

     

    7.9.       Stool Banks

    7.9.1.    Introduction to Stool Banks

    7.9.2.    List of Stool Banks

     

    7.9.3.    Profiles of Prominent Stool Banks

    7.9.3.1. AdvancingBio

    7.9.3.1.1. Overview

    7.9.3.1.2. Fecal Microbiota Preparation

     

    7.9.3.2. Asia Microbiota bank

    7.9.3.2.1. Overview

    7.9.3.2.2. Fecal Microbiota Preparation

     

    7.9.3.3. Enterobiotix

    7.9.3.3.1. Overview

    7.9.3.3.2. Fecal Microbiota Preparation

     

    7.9.3.4. Flora Medicine

    7.9.3.4.1. Overview

    7.9.3.4.2. Fecal Microbiota Preparation

     

    7.9.3.5. OpenBiome

    7.9.3.5.1. Overview

    7.9.3.5.2. Fecal Microbiota Preparation

     

    1. ATTRACTIVENESS COMPETITIVENESS (AC) MATRIX

    8.1.       Chapter Overview

    8.2.       AC Matrix: An Overview

    8.2.1.    Strong Opportunity Areas

    8.2.2.    Average Opportunity Areas

    8.2.3.    Weak Opportunity Areas

     

    8.3.       AC Matrix: Analytical Methodology

    8.4.       AC Matrix: Plotting the Information

    8.5.       AC Matrix: Analyzing the Data

    8.5.1.    Strong Opportunity Areas

    8.5.2.    Average Opportunity Areas

    8.5.3.    Weak Opportunity Areas

     

    1. MICROBIOME RELATED INITIATIVES OF BIG PHARMACEUTICAL PLAYERS

    9.1.       Chapter Overview

    9.2.       Scope and Methodology

     

    9.3.       Initiatives of Big Pharmaceutical Players

    9.3.1.    Analysis by Portfolio Diversity

    9.3.2.    Analysis by Phase of Development

    9.3.3.    Analysis by Type of Molecule

    9.3.4.    Analysis by Type of Therapy

    9.3.5.    Analysis by Diversity of Therapeutic Areas

     

    9.4.       Benchmark Analysis of Big Pharmaceutical Players

    9.4.1.    Spider Web Analysis: Company A

    9.4.2.    Spider Web Analysis: Company B

    9.4.3.    Spider Web Analysis: Company C

    9.4.4.    Spider Web Analysis: Company D

    9.4.5.    Spider Web Analysis: Company E

    9.4.6.    Spider Web Analysis: Company F

    9.4.7.    Spider Web Analysis: Company G

    9.4.8.    Spider Web Analysis: Company H

    9.4.9.    Spider Web Analysis: Company I

    9.4.10.  Spider Web Analysis: Company J

    9.4.11.  Spider Web Analysis: Company K

     

    1. START-UP HEALTH INDEXING

    10.1.     Chapter Overview

    10.2.     Scope and Methodology

    10.3.     Benchmark Analysis of Start-ups

    10.3.1.  Benchmark Analysis by Portfolio Diversity

    10.3.2.  Benchmark Analysis by Phase of Development

    10.3.3.  Benchmark Analysis by Diversity in Therapeutic Areas

    10.3.4.  Benchmark Analysis by Funding Amount

    10.3.5.  Benchmark Analysis by Number of Investors

    10.3.6.  Benchmark Analysis by Progression in Funding

    10.3.7.  Benchmark Analysis by Partnership Activity

    10.3.8.  Benchmark Analysis by Patent Portfolio

    10.3.9.  Start-up Health Indexing: Roots Analysis Perspective

    10.3.9.1. Short Profiles of Top Five Players

    10.3.9.1.1. Evelo Biosciences

    10.3.9.1.2. AOBiome Therapuetics

    10.3.9.1.3. SFA Therapeutics

    10.3.9.1.4. Azitra

    10.3.9.1.5. Axial Biotherapeutics

     

    1. KEY THERAPEUTIC AREAS

    11.1.     Chapter Overview

    11.2.     Metabolic Disorders

    11.2.1.  Diabetes

    11.2.1.1. Disease Description

    11.2.1.2. Associated Health Risks / Complications

    11.2.1.3. Epidemiology

    11.2.1.4. Disease Diagnosis

    11.2.1.5. Current Treatment Options

    11.2.1.5.1. Insulin Therapies

    11.2.1.5.2. Non-Insulin Therapies

    11.2.1.6. Side Effects of Current Treatment Options

    11.2.1.7. Microbiome Therapeutics for Diabetes

     

    11.2.2.  Lactose Intolerance

    11.2.2.1. Disease Description

    1.2.2.2. Epidemiology

    11.2.2.3. Current Treatment Options

    11.2.2.4. Microbiome Therapeutics for Lactose Intolerance

     

    11.2.3.  Nonalcoholic Steatohepatitis (NASH)

    11.2.3.1. Disease Description

    11.2.3.2. Epidemiology

    11.2.3.3. Current Treatment Options

    11.2.3.4. Microbiome Therapeutics for NASH

     

    11.2.4.  Primary Hyperoxaluria

    11.2.4.1. Disease Description

    11.2.4.2. Epidemiology

    11.2.4.3. Current Treatment Options

    11.2.4.4. Microbiome Therapeutics for Primary Hyperoxaluria

     

    11.2.5.  Obesity

    11.2.5.1. Disease Description

    11.2.5.2. Epidemiology

    11.2.5.3. Current Treatment Options

    11.2.5.4. Side Effects of Current Treatment Options

    11.2.5.5. Microbiome Therapeutics for Obesity

     

    11.3.     Digestive and Gastrointestinal Disorders

    11.3.1.  Crohn’s Disease

    11.3.1.1. Disease Description

    11.3.1.2. Epidemiology

    11.3.1.3. Current Treatment Options

    11.3.1.4. Side Effects of Current Treatment Options

    11.3.1.5. Microbiome Therapeutics for Crohn’s Disease

     

    11.3.2.  Irritable Bowel Syndrome (IBS)

    11.3.2.1. Disease Description

    11.3.2.2. Epidemiology

    11.3.2.3. Current Treatment Options

    11.3.2.4. Microbiome Therapeutics for IBS

     

    11.3.3.  Ulcerative Colitis

    11.3.3.1. Disease Description

    11.3.3.2. Epidemiology

    11.3.3.3. Current Treatment Options

    11.3.3.4. Side Effects of Current Treatment Options

    11.3.3.5. Microbiome Therapeutics for Ulcerative Colitis

     

    11.4.     Oncological Indications

    11.4.1.  Colorectal Cancer

    11.4.1.1. Disease Description

    11.4.1.2. Epidemiology

    11.4.1.3. Current Treatment Options

    11.4.1.4. Side Effects of Current Treatments

    11.4.1.5. Microbiome Therapeutics for Colorectal Cancer

                           

    11.4.2.  Lung Cancer

    11.4.2.1. Disease Description

    11.4.2.2. Epidemiology

    11.4.2.3. Current Treatment Options

    11.4.2.4. Side Effects of Current Treatment Options

    11.4.2.5. Microbiome Therapeutics for Lung Cancer

     

    11.5.     Dermatological Disorders

    11.5.1.  Acne Vulgaris

    11.5.1.1. Disease Description

    11.5.1.2. Epidemiology

    11.5.1.3. Current Treatment Options

    11.5.1.4. Side Effects of Current Treatment Options

    11.5.1.5. Microbiome Therapeutics for Acne Vulgaris

     

    11.6.     Infectious Diseases

    11.6.1.  Clostridium Difficile Infections (CDIs)

    11.6.1.1. Description

    11.6.1.2. Epidemiology

    11.6.1.3. Disease Diagnosis

    11.6.1.4. Current Treatment Options

    11.6.1.5. Side Effects of Current Treatment Options

    11.6.1.6. Microbiome Therapeutics for CDI

     

    11.6.2.  Bacterial Vaginosis

    11.6.2.1. Disease Description

    11.6.2.2. Epidemiology

    11.6.2.3. Current Treatment Options

    11.6.2.4. Side Effects of Current Treatment Options

    11.6.2.5. Microbiome Therapeutics for Bacterial Vaginosis

     

    1. FUNDING AND INVESTMENT ANALYSIS

    12.1.     Chapter Overview

    12.2.     Types of Funding

     

    12.3.     Microbiome Therapeutics and Diagnostics: List of Funding and Investments

    12.3.1.  Analysis by Number of Instances

    12.3.2. Analysis by Amount Invested

    12.3.3. Analysis by Type of Funding

    12.3.4. Analysis by Type of Company

    12.3.5. Analysis by Purpose of Funding

    12.3.6. Analysis by Type of Molecule

    12.3.7. Analysis by Target Indication

    12.3.8. Analysis by Therapeutic Area

    12.3.9.  Analysis by Geography

    12.3.10. Most Active Players

    12.3.11. Most Active Investors

    12.3.12.  Analysis by Type of Investors

    12.3.13. Analysis by Location of Investors

    12.4.     Concluding Remarks

     

    1. CONTRACT SERVICES FOR MICROBIOME THERAPEUTICS

    13.1.     Chapter Overview

    13.2.     Manufacturing Microbiome Therapeutics

    13.2.1.  Key Steps Involved

    13.2.2.  Associated Challenges

    13.2.3.  Growing Demand for Contract Manufacturing Services

     

    13.2.4.  Contract Manufacturing Organizations (CMOs)

    13.2.4.1. Introduction to Contract Manufacturing

    13.2.4.2. List of Organizations Offering Services for Microbiome Therapeutics

     

    13.2.5.  In-House Manufacturers

    13.2.5.1. Introduction to In-House Manufacturing

    13.2.5.2. List of In-House Manufacturers

     

    13.3.     Microbiome Therapeutics-related R&D

    13.3.1.  Growing Demand for Contract Research Services

    13.3.2.  Contract Research Organizations (CROs)

    13.3.2.1. Introduction to Contract Research

    13.3.2.2. List of Organizations Offering Services for Microbiome Therapeutics

     

    13.4.     Key Considerations for Selecting a Suitable CMO / CRO Partner

     

    1. BIG DATA AND MICROBIOME THERAPEUTICS

    14.1.     Chapter Overview

    14.2.     Introduction to Big Data

    14.3.     Internet of Things

    14.4.     Growing Interest in Big Data: Google Trends Analysis

    14.5.     Key Application Areas

     

    14.6.     Big Data in Microbiome Research

    14.6.1.  Microbiome Data and Personalized Medicine

    14.6.2.  Microbiome-related Data Management Challenges

    14.6.3.  National Microbiome Data Center

     

    14.7.     Big Data Services for Microbiome Research: List of Companies

    14.8.     Big Data Services for Microbiome Research: Profiles of Key Players

    14.8.1.  Human Longevity

    14.8.1.1. Company Overview

    14.8.1.2. Technology and Service Portfolio

    14.8.1.3. Recent Developments

     

    14.8.2.  Resilient Biotics

    14.8.2.1. Company Overview

    14.8.2.2. Technology and Service Portfolio

    14.8.2.3. Recent Developments

     

    14.8.3.  Resphera Biosciences

    14.8.3.1. Company Overview

    14.8.3.2. Technology and Service Portfolio

     

    1. MICROBIOME THERAPEUTICS: MARKET FORECAST AND OPPORTUNITY ANALYSIS

    15.1.     Chapter Overview

    15.2.     Scope and Limitations

    15.3.     Forecast Methodology

     

    15.4.     Overall Microbiome Therapeutics Market, 2019-2030

    15.4.1.  Microbiome Therapeutics Market: Distribution by Type of Therapy, 2025 and 2030

    15.4.1.1. Microbiome Therapeutics Market for Prescription Drugs, 2019-2030

    15.4.1.2. Microbiome Therapeutics Market for Prebiotic Drugs, 2019-2030

    15.4.1.3. Microbiome Therapeutics Market for Probiotic Drugs, 2019-2030

     

    15.4.2.  Microbiome Therapeutics Market: Distribution by Type of Molecule, 2025 and 2030

    15.4.2.1. Microbiome Therapeutics Market for Small Molecules, 2019-2030

    15.4.2.2. Microbiome Therapeutics Market for Biologics, 2019-2030

     

    15.4.3.  Microbiome Therapeutics Market: Distribution by Target Indication, 2025 and 2030

    15.4.3.1. Microbiome Therapeutics Market for Acne Vulgaris, 2019-2030

    15.4.3.2. Microbiome Therapeutics Market for Atopic Dermatitis, 2019-2030

    15.4.3.3. Microbiome Therapeutics Market for CDI, 2019-2030

    15.4.3.4. Microbiome Therapeutics Market for Crohn’s Disease, 2019-2030

    15.4.3.5. Microbiome Therapeutics Market for Dental Caries, 2019-2030

    15.4.3.6. Microbiome Therapeutics Market for Diabetes, 2019-2030

    15.4.3.7. Microbiome Therapeutics Market for IBS, 2019-2030

    15.4.3.8. Microbiome Therapeutics Market for Lactose Intolerance, 2019-2030

    15.4.3.9. Microbiome Therapeutics Market for Lung Cancer, 2019-2030

    15.4.3.10. Microbiome Therapeutics Market for NASH, 2019-2030

    15.4.3.11. Microbiome Therapeutics Market for Primary Hyperoxaluria, 2019-2030

    15.4.3.12. Microbiome Therapeutics Market for Psoriasis, 2019-2030

    15.4.3.13. Microbiome Therapeutics Market for Ulcerative Colitis, 2019-2030

     

    15.4.4.  Microbiome Therapeutics Market: Distribution by Therapeutic Area, 2025 and 2030

    15.4.4.1. Microbiome Therapeutics Market for Autoimmune Disorders, 2019-2030

    15.4.4.2. Microbiome Therapeutics Market for Dental Disorders, 2019-2030

    15.4.4.3. Microbiome Therapeutics Market for Digestive and Gastrointestinal Disorders, 2019-2030

    15.4.4.4. Microbiome Therapeutics Market for Dermatological Disorders, 2019-2030

    15.4.4.5. Microbiome Therapeutics Market for Infectious Diseases, 2019-2030

    15.4.4.6. Microbiome Therapeutics Market for Metabolic Disorders, 2019-2030

    15.4.4.7. Microbiome Therapeutics Market for Oncology, 2019-2030

     

    15.4.5.  Microbiome Therapeutics Market: Distribution by Key Geographical Regions, 2025 and 2030

    15.4.5.1. Microbiome Therapeutics Market in North America, 2019-2030

    15.4.5.2. Microbiome Therapeutics Market in Europe, 2019-2030

    15.4.5.3. Microbiome Therapeutics Market in Asia-Pacific and Rest of the World, 2019-2030

    15.4.6.  Microbiome Therapeutics Market: Distribution by Leading Drug Developers, 2025 and 2030

    15.5.     Microbiome Therapeutics Market: Distribution by Leading Therapeutic Products, 2019-2030

    15.5.1.  Drug-wise Sales Forecast

    15.5.1.1. IBP-9414 (Infant Bacterial Therapeutics)

    15.5.1.2. Sales Forecast (USD Million)

    15.5.1.3. Net Present Value (USD Million)

    15.5.1.4. Value Creation Analysis

     

    15.5.2.1. Oxabact (OxThera)

    15.5.2.2. Sales Forecast (USD Million)

    15.5.2.3. Net Present Value (USD Million)

    15.5.2.4. Value Creation Analysis

     

    15.5.3.1. RBX2660 (Rebiotix)

    15.5.3.2. Sales Forecast (USD Million)

    15.5.3.3. Net Present Value (USD Million)

    15.5.3.4. Value Creation Analysis

     

    15.5.4.1. RP-G28 (Ritter Pharmaceuticals)

    15.5.4.2. Sales Forecast (USD Million)

    15.5.4.3. Net Present Value (USD Million)

    15.5.4.4. Value Creation Analysis

     

    15.5.5.1. SER-109 (Seres Therapeutics)

    15.5.5.2. Sales Forecast (USD Million)

    15.5.5.3. Net Present Value (USD Million)

    15.5.5.4. Value Creation Analysis

     

    1. MICROBIOME DIAGNOSTICS: MARKET FORECAST AND OPPORTUNITY ANALYSIS

    16.1.     Chapter Overview

    16.2.     Scope and Limitations

    16.3      Forecast Methodology

    16.4.     Overall Microbiome Diagnostics Market, 2019-2030

    16.4.1.  Overall Microbiome Diagnostics Market, 2019-2030 (By Value)

    16.4.2.  Overall Microbiome Diagnostics Market, 2019-2030 (By Volume)

     

    16.5.     Microbiome Diagnostics Market: Distribution by Target Indications, 2019, 2030

    16.5.1.  Microbiome Diagnostics Market: Distribution by Target Indications, 2019 and 2030 (By Value)

    16.5.1.1. Microbiome Diagnostics Market for Colorectal Cancer, 2019-2030 (By Value)

    16.5.1.2. Microbiome Diagnostics Market for Diabetes, 2019-2030 (By Value)

    16.5.1.3. Microbiome Diagnostics Market for IBD, 2019-2030 (By Value)

    16.5.1.4. Microbiome Diagnostics Market for IBS, 2019-2030 (By Value)

    16.5.1.5. Microbiome Diagnostics Market for NASH, 2019-2030 (By Value)

    16.5.1.6. Microbiome Diagnostics Market for Obesity, 2019-2030 (By Value)

    16.5.1.7. Microbiome Diagnostics Market for Others, 2019-2030 (By Value)

     

    16.5.2.  Microbiome Diagnostics Market: Distribution by Target Indications, 2019 and 2030 (By Volume)

    16.5.2.1. Microbiome Diagnostics Market for Colorectal Cancer, 2019-2030 (By Volume)

    16.5.2.2. Microbiome Diagnostics Market for Diabetes, 2019-2030 (By Volume)

    16.5.2.3. Microbiome Diagnostics Market for IBD, 2019-2030 (By Volume)

    16.5.2.4. Microbiome Diagnostics Market for IBS, 2019-2030 (By Volume)

    16.5.2.5. Microbiome Diagnostics Market for NASH, 2019-2030 (By Volume)

    16.5.2.6. Microbiome Diagnostics Market for Obesity, 2019-2030 (By Volume)

    16.5.2.7. Microbiome Diagnostics Market for Others, 2019-2030 (By Volume)

     

    16.6.     Microbiome Diagnostics Market: Distribution by Therapeutic Areas, 2019-2030

    16.6.1.  Microbiome Diagnostics Market: Distribution by Therapeutic Areas, 2019 and 2030 (By Value)

    16.6.1.2. Microbiome Diagnostics Market for Digestive and Gastrointestinal Disorders, 2019-2030 (By Value)

    16.6.1.2. Microbiome Diagnostics Market for Metabolic Disorders, 2019-2030 (By Value)

    16.6.1.3. Microbiome Diagnostics Market for Oncology, 2019-2030 (By Value)

    16.6.1.4. Microbiome Diagnostics Market for Others, 2019-2030 (By Value)

     

    16.6.2.  Microbiome Diagnostics Market: Distribution by Therapeutic Areas, 2019 and 2030 (By Volume)

    16.6.2.1. Microbiome Diagnostics Market for Digestive and Gastrointestinal Disorders, 2019-2030 (By Volume)

    16.6.2.2. Microbiome Diagnostics Market for Metabolic Disorders, 2019-2030 (By Volume)

    16.6.2.3. Microbiome Diagnostics Market for Oncology, 2019-2030 (By Volume)

    16.6.2.4. Microbiome Diagnostics Market for Others, 2019-2030 (By Volume)

     

    16.7.     Microbiome Diagnostics Market: Distribution by Key Geographical Regions, 2019-2030

    16.7.1.  Microbiome Diagnostics Market: Distribution by Key Geographical Regions, 2019 and 2030 (By Value)

    16.7.1.1. Microbiome Diagnostics Market in North America, 2019-2030 (By Value)

    16.7.1.2. Microbiome Diagnostics Market in Europe, 2019-2030 (By Value)

    16.7.1.3. Microbiome Diagnostics Market in Asia-Pacific and Rest of the World, 2019-2030 (By Value)

     

    16.7.2.  Microbiome Diagnostics Market: Distribution by Key Geographical Regions, 2019 and 2030 (By Volume)

    16.7.2.1. Microbiome Diagnostics Market in North America, 2019-2030 (By Volume)

    16.7.2.2. Microbiome Diagnostics Market in Europe, 2019-2030 (By Volume)

    16.7.2.3. Microbiome Diagnostics Market in Asia-Pacific and Rest of the World, 2019-2030 (By Volume)

     

    1. FECAL MICROBIOTA THERAPIES: MARKET FORECAST AND OPPORTUNITY ANALYSIS

    17.1.     Chapter Overview

    17.2.     Scope and Limitations

    17.3.     Forecast Methodology

    17.4.     Overall FMT Market, 2019-2030

    17.4.1.  Overall FMT Market, 2019-2030 (By Value)

    17.4.2.  Overall FMT Market, 2019-2030 (By Volume)

     

    17.5.     Overall Microbiome Market by Product Offerings, 2019-2030

     

    1. CASE STUDY: MICROBIOME-BASED PRODUCTS IN OTHER INDUSTRIES

    18.1.     Chapter Overview

    18.2.     List of Microbiome Products in Other Industries

    18.2.1.  Applications of Microbiome Based Products in Cosmetics and Food Industry

    18.3.     Applications of Microbiome Based Products in Agriculture Industry

    18.4.     Future Prospects

     

    1. CONCLUDING REMARKS

     

    1. EXECUTIVE INSIGHTS

    20.1      Chapter Overview

    20.2.     Floragraph

    20.2.1.  Company / Organization Snapshot

    20.2.2.  Interview Transcript: Alicia Scheffer, Chief Executive Officer

     

    20.3.     Rebiotix

    20.3.1.  Company / Organization Snapshot

    20.3.2.  Interview Transcript: Lee Jones, President and Chief Executive Officer

     

    20.4.     S-Biomedic

    20.4.1.  Company / Organization Snapshot

    20.4.2.  Interview Transcript: Veronika Oudova, Co-founder and Chief Executive Officer

     

    20.5.     Whole Biome

    20.5.1.  Company / Organization Snapshot

    20.5.2.  Interview Transcript: Colleen Cutcliffe, Co-founder and Chief Executive Officer

     

    20.6.     Siolta Therapeutics

    20.6.1.  Company / Organization Snapshot

    20.6.2.  Interview Transcript: Nikole E Kimes, Co-founder and Vice President

     

    20.7.     OpenBiome

    20.7.1.  Company / Organization Snapshot

    20.7.2.  Interview Transcript: James Burges, Executive Director

     

    20.8.     Assembly Biosciences

    20.8.1.  Company / Organization Snapshot

    20.8.2.  Interview Transcript: JP Benya, Vice President, Business Development

                           

    20.9.     List Biological Laboratories

    20.9.1.  Company / Organization Snapshot

    20.9.2.  Interview Transcript: Debbie Pinkston, Vice President, Sales and Business Development

     

    20.10.   Metabiomics

    20.10.1. Company / Organization Snapshot

    20.10.2. Interview Transcript: Gregory J Kuehn, Vice President, Business Development and Marketing

     

    20.11.   MicroBiome Therapeutics

    20.11.1. Company / Organization Snapshot

    20.11.2. Interview Transcript: Mark Heiman, Chief Scientific Officer and Vice President, Research

     

    20.12.   Universal Stabilization Technologies

    20.12.1. Company / Organization Snapshot

    20.12.2. Interview Transcript: Alexander Segal, Vice President, Business Development

     

    20.13.   BiomX

    20.13.1. Company / Organization Snapshot

    20.13.2. Interview Transcript: Assaf Oron, Chief Business Officer

     

    20.14.   Da Volterra

    20.14.1. Company / Organization Snapshot

    20.14.2. Interview Transcript: Pierre-Alain Bandinelli, Chief Business Officer

     

    20.15.   Chung Mei Pharmaceutical

    20.15.1. Company / Organization Snapshot

    20.15.2. Interview Transcript: Alexander Lin, Associate General Manager

     

    20.16.   Pacific Northwest National Laboratories

    20.16.1. Company / Organization Snapshot

    20.16.2. Interview Transcript: Aaron Wright, Senior Scientist

     

    1. APPENDIX I: TABULATED DATA

     

    1. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

     

    Contact Details

    Gaurav Chaudhary

    +1 (415) 800 3415

    gaurav.chaudhary@rootsanalysis.com


  • Human Microbiome-based Products Market is projected to be worth USD 4 Billion by 2030

    Over the years, extensive R&D efforts have enabled microbiome-based therapy / diagnostic developers to make significant strides, in terms of progressing proprietary product candidates into the clinic

     

    Roots Analysis has announced the addition of “Human Microbiome Market, 2019-2030” report to its list of offerings

     

    The report features an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain. In addition to other elements, the study includes:

    • A detailed assessment of the current market landscape of microbiome therapeutics, providing information on drug / therapy developer(s).
    • Elaborate profiles of key players (established after 2005) that are engaged in the development of microbiome therapeutics.
    • A detailed review of the current market landscape of microbiome diagnostic tests, brief profiles of popular diagnostic developers and indicative list of screening and profiling test kits.
    • A detailed assessment of the current market landscape of FMT therapies, a geographical clinical trial analysis and information on various stool banks.
    • A detailed business portfolio analysis based on an attractiveness and competitiveness (AC) framework.
    • An analysis of the varied microbiome-focused initiatives of big pharma players.
    • An analysis of the start-ups / small-sized players engaged in the development of microbiome therapeutics and diagnostics.
    • An assessment of the most commonly targeted therapeutic indications and details of microbiome-based drugs.
    • An analysis of the investments made at various stages of development in start-ups / small-sized companies.
    • An indicative list of contract manufacturers, in-house manufacturers and CROs that currently claim to have the necessary capabilities.
    • An assessment of the emerging role of big data highlighting efforts focused on the development and implementation of various algorithms / tools to analyze data generated from in the microbiome research.
    • An informative case study on the various other applications of microbiome products, such as agriculture, animal health, plant health, food products
    • A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)

    segments:

    • Type of Therapy (Tx)
    • Prescription Drug
    • Prebiotics
    • Probiotics

                       

    • Type of Molecule (Tx)
    • Small Molecules
    • Biologics

     

    • Target Indication (Tx+Dx)
    • Acne Vulgaris
    • Atopic Dermatitis
    • Clostridium difficile Infection
    • Colorectal Cancer
    • Crohn’s Disease
    • Diabetes
    • Irritable Bowel Syndrome
    • Lactose Intolerance
    • Lung Cancer
    • Nonalcoholic steatohepatitis (NASH)
    • Obesity
    • Ulcerative colitis

     

    • Therapeutic Area (Tx+Dx)
    • Autoimmune Disorders
    • Dental Disorders
    • Digestive and Gastrointestinal Disorders
    • Dermatological Disorders
    • Infectious Disease
    • Metabolic Disorders
    • Oncology
    • Others

     

    • Key Geographical Regions (Tx+Dx)
    • North America
    • Europe
    • Asia-Pacific and Rest of the World

     

    Key companies covered in the report

    • 4D Pharma
    • Armata Pharmaceuticals
    • Evelo Biosciences
    • Rebiotix (Acquired by Ferring Pharmaceuticals)
    • Seres Therapeutics
    • Vedanta Biosciences

     

    For more information please click on the following link: 

    https://www.rootsanalysis.com/reports/view_document/human-microbiome-market/281.html or email sales@rootsanalysis.com

     

    Other Recent Offerings:

    1. Antibody Drug Conjugates Market (5th Edition), 2019-2030
    2. Gene Therapy Market (3rd Edition), 2019 - 2030
    3. Global T-Cell (CAR-T, TCR, and TIL) Therapy Market (4th Edition), 2019 – 2030
    4. Synthetic Lethality-based Drugs and Targets Market, 2019-2030

     

     

    About Roots Analysis

    Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

     

    Contact Information

    Roots Analysis Private Limited

    Gaurav Chaudhary

    +1 (415) 800 3415

    gaurav.chaudhary@rootsanalysis.com


  • The “HPAPI and Cytotoxic Drugs Manufacturing Market (3rd Edition), 2020-2030” report

    Key Inclusions

    • A detailed review of the overall landscape of companies offering contract services for the manufacturing of HPAPIs and cytotoxic drugs, along with information on year of establishment, company size, scale of operation (preclinical, clinical and commercial), location of headquarters, number and location of manufacturing facilities, facility size, type of service(s) offered (clinical manufacturing, commercial manufacturing, analytical testing, scale-up, process development / pre-formulation, formulation development, stability studies, regulatory support and fill / finish and packaging), type of product manufactured (HPAPIs and highly potent finished dosage forms), type of pharmacological molecule (biologics and small molecules), type of highly potent finished dosage form manufactured (capsules, granules, injectables, liquids and tablets), and type of primary packaging used (ampoules, blisters, prefilled syringes, conventional syringes, vials and others).
    • A competitiveness analysis of HPAPI and cytotoxic drugs contract manufacturers, taking into consideration supplier strength (based on company size and its experience in this field) and service strength (based on scale of operation, type of service(s) offered, type of product(s) manufactured, number and location of manufacturing facilities, type of highly potent finished dosage forms manufactured and type of primary packaging used).
    • Elaborate profiles of the key players (shortlisted based on a proprietary criterion) that offer a diverse range of capabilities for the development, manufacturing and packaging of HPAPIs and cytotoxic drugs, across North America, Europe and Asia Pacific. Each profile includes a brief overview of the company, its year of establishment, location of headquarters, number of employees and financial information (if available). In addition to this, the profile includes information on the various HPAPIs / cytotoxic dugs manufacturing services offered by the company, along with the location of their manufacturing facilities. Further, we have provided the recent developments of the company and an informed future outlook.
    • An analysis of the various partnerships pertaining to the contract manufacturing of HPAPIs and cytotoxic drugs, which have been established since 2014, based on several parameters, such as the year of partnership, type of partnership, type of product, scale of operation, company size, amount invested in acquisitions, most active player and geographical analysis.
    • An analysis of the various expansion initiatives undertaken by service providers, in order to augment their respective HPAPI and cytotoxic drug manufacturing capabilities, over the period 2014-2019, taking into consideration several relevant parameters, such as year of expansion, type of expansion (capacity expansion, facility expansion and new facility), scale of operation (preclinical, clinical and commercial), type of product manufactured (HPAPIs and highly potent finished dosage forms), and location of manufacturing facility.
    • An estimate of the overall, installed capacity for manufacturing HPAPIs and cytotoxic drugs based on data reported by industry stakeholders in the public domain; it highlights the distribution of available HPAPIs and cytotoxic drugs production capacity on the basis of company size (small-sized, mid-sized, large and very large companies), scale of operation (preclinical, clinical and commercial), and across key geographical regions (North America, Europe, Asia Pacific and rest of the world).
    • A qualitative analysis, highlighting the various factors that need to be taken into consideration by highly potent drug developers while deciding whether to manufacture their respective products in-house or engage the services of a CMO.
    • A discussion on affiliated trends, key drivers and challenges which are likely to impact the industry’s evolution, under a comprehensive SWOT framework; it includes a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall industry.
    • A case study on the antibody drug conjugates (ADCs) manufacturing market, highlighting a list of contract service providers and in-house manufacturers that are currently active in this space. Additionally, it includes a detailed set of analyses of these companies based on several parameters, such as year of establishment, company size, scale of operation (preclinical, clinical and commercial), location of headquarters, number and location of manufacturing facilities, and type of service(s) offered.

     

    The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:

    • Type of Product
    • HPAPIs
    • Highly Potent Finished Dosage Forms

     

    • Company Size
    • Small-sized
    • Mid-sized
    • Large / Very Large

     

    • Scale of Operation
    • Preclinical / Clinical
    • Commercial

     

    • Type of Pharmacological Molecule
    • Small Molecules
    • Biologics

     

    • Type of Highly Potent Finished Dosage Form
    • Injectables
    • Oral Solids
    • Creams
    • Others

     

    • Key geographical regions
    • North America
    • Europe
    • Asia Pacific
    • Rest of the World

     

    To request sample pages, please visit this link

     

    Key Questions Answered

    • Who are the key manufacturers of HPAPIs and cytotoxic drugs, across the world?
    • What kind of partnership models are commonly adopted by stakeholders in this domain?
    • What is the current, installed contract manufacturing capacity for HPAPIs?
    • What are the key factors influencing the make (manufacture in-house) versus buy (outsource) decision related to HPAPIs and cytotoxic drugs?
    • What are the key drivers and growth constraints in HPAPI and cytotoxic drugs manufacturing market?
    • How is the current and future market opportunity likely to be distributed across key market segments?

     

    You may also be interested in the following titles:

    1. Antibody Contract Manufacturing Market, 2020 – 2030
    2. Cell Therapy Manufacturing Market (3rd Edition), 2019 – 2030
    3. Biopharma Contract Manufacturing Market (3rd Edition), 2019 – 2030

     

    Contact Us

    Gaurav Chaudhary

    +1 (415) 800 3415

    gaurav.chaudhary@rootsanalysis.com


  • The “HPAPI and Cytotoxic Drugs Manufacturing Market (3rd Edition), 2020-2030” report

    Key Inclusions

    • A detailed review of the overall landscape of companies offering contract services for the manufacturing of HPAPIs and cytotoxic drugs, along with information on year of establishment, company size, scale of operation (preclinical, clinical and commercial), location of headquarters, number and location of manufacturing facilities, facility size, type of service(s) offered (clinical manufacturing, commercial manufacturing, analytical testing, scale-up, process development / pre-formulation, formulation development, stability studies, regulatory support and fill / finish and packaging), type of product manufactured (HPAPIs and highly potent finished dosage forms), type of pharmacological molecule (biologics and small molecules), type of highly potent finished dosage form manufactured (capsules, granules, injectables, liquids and tablets), and type of primary packaging used (ampoules, blisters, prefilled syringes, conventional syringes, vials and others).
    • A competitiveness analysis of HPAPI and cytotoxic drugs contract manufacturers, taking into consideration supplier strength (based on company size and its experience in this field) and service strength (based on scale of operation, type of service(s) offered, type of product(s) manufactured, number and location of manufacturing facilities, type of highly potent finished dosage forms manufactured and type of primary packaging used).
    • Elaborate profiles of the key players (shortlisted based on a proprietary criterion) that offer a diverse range of capabilities for the development, manufacturing and packaging of HPAPIs and cytotoxic drugs, across North America, Europe and Asia Pacific. Each profile includes a brief overview of the company, its year of establishment, location of headquarters, number of employees and financial information (if available). In addition to this, the profile includes information on the various HPAPIs / cytotoxic dugs manufacturing services offered by the company, along with the location of their manufacturing facilities. Further, we have provided the recent developments of the company and an informed future outlook.
    • An analysis of the various partnerships pertaining to the contract manufacturing of HPAPIs and cytotoxic drugs, which have been established since 2014, based on several parameters, such as the year of partnership, type of partnership, type of product, scale of operation, company size, amount invested in acquisitions, most active player and geographical analysis.
    • An analysis of the various expansion initiatives undertaken by service providers, in order to augment their respective HPAPI and cytotoxic drug manufacturing capabilities, over the period 2014-2019, taking into consideration several relevant parameters, such as year of expansion, type of expansion (capacity expansion, facility expansion and new facility), scale of operation (preclinical, clinical and commercial), type of product manufactured (HPAPIs and highly potent finished dosage forms), and location of manufacturing facility.
    • An estimate of the overall, installed capacity for manufacturing HPAPIs and cytotoxic drugs based on data reported by industry stakeholders in the public domain; it highlights the distribution of available HPAPIs and cytotoxic drugs production capacity on the basis of company size (small-sized, mid-sized, large and very large companies), scale of operation (preclinical, clinical and commercial), and across key geographical regions (North America, Europe, Asia Pacific and rest of the world).
    • A qualitative analysis, highlighting the various factors that need to be taken into consideration by highly potent drug developers while deciding whether to manufacture their respective products in-house or engage the services of a CMO.
    • A discussion on affiliated trends, key drivers and challenges which are likely to impact the industry’s evolution, under a comprehensive SWOT framework; it includes a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall industry.
    • A case study on the antibody drug conjugates (ADCs) manufacturing market, highlighting a list of contract service providers and in-house manufacturers that are currently active in this space. Additionally, it includes a detailed set of analyses of these companies based on several parameters, such as year of establishment, company size, scale of operation (preclinical, clinical and commercial), location of headquarters, number and location of manufacturing facilities, and type of service(s) offered.

     

    The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:

    • Type of Product
    • HPAPIs
    • Highly Potent Finished Dosage Forms

     

    • Company Size
    • Small-sized
    • Mid-sized
    • Large / Very Large

     

    • Scale of Operation
    • Preclinical / Clinical
    • Commercial

     

    • Type of Pharmacological Molecule
    • Small Molecules
    • Biologics

     

    • Type of Highly Potent Finished Dosage Form
    • Injectables
    • Oral Solids
    • Creams
    • Others

     

    • Key geographical regions
    • North America
    • Europe
    • Asia Pacific
    • Rest of the World

     

    To request sample pages, please visit this link

     

    Key Questions Answered

    • Who are the key manufacturers of HPAPIs and cytotoxic drugs, across the world?
    • What kind of partnership models are commonly adopted by stakeholders in this domain?
    • What is the current, installed contract manufacturing capacity for HPAPIs?
    • What are the key factors influencing the make (manufacture in-house) versus buy (outsource) decision related to HPAPIs and cytotoxic drugs?
    • What are the key drivers and growth constraints in HPAPI and cytotoxic drugs manufacturing market?
    • How is the current and future market opportunity likely to be distributed across key market segments?

     

    You may also be interested in the following titles:

    1. Antibody Contract Manufacturing Market, 2020 – 2030
    2. Cell Therapy Manufacturing Market (3rd Edition), 2019 – 2030
    3. Biopharma Contract Manufacturing Market (3rd Edition), 2019 – 2030

     

    Contact Us

    Gaurav Chaudhary

    +1 (415) 800 3415

    gaurav.chaudhary@rootsanalysis.com


  • Close to 120 companies across the globe claim to possess the required expertise

    Development initiatives of HPAPIs and cytotoxic drugs are generally very demanding, both in terms of experience and capital investment. Most companies generally lack the necessary resources to meet the aforementioned requirements and are unable to set up dedicated HPAPI and cytotoxic drug manufacturing facilities. This has led to an increased demand for contract manufacturing service providers in this field.

     

    To order this 300+ page report, which features 75+ figures and 150+ tables, please visit this link

     

    The USD 25 billion (by 2030) financial opportunity within the HPAPI and cytotoxic drugs contract manufacturing market has been analyzed across the following segments:

    • Type of Product
    • HPAPIs
    • Highly Potent Finished Dosage Forms

     

    • Company Size
    • Small-sized
    • Mid-sized
    • Large / Very Large

     

    • Scale of Operation
    • Preclinical / Clinical
    • Commercial

     

    • Type of Pharmacological Molecule
    • Small Molecules
    • Biologics

     

    • Type of Highly Potent Finished Dosage Form
    • Injectables
    • Oral Solids
    • Creams
    • Others

     

    • Key geographical regions
    • North America
    • Europe
    • Asia Pacific
    • Rest of the World

     

    The “HPAPI and Cytotoxic Drugs Manufacturing (3rd Edition) 2020-2030 report features the following companies, which we identified to be key players in this domain:

    • AbbVie Contract Manufacturing
    • CARBOGEN AMCIS
    • Catalent
    • Evonik
    • Formosa Laboratories
    • Intas
    • Lonza
    • MabPlex
    • Pfizer CentreOne

     

    Table of Contents

     

    1. Preface

      2. Executive Summary

    2. Introduction

    3. Market Landscape

    4. Company Competitive Analysis

    5. HPAPI and Cytotoxic Drugs Contract Manufacturers based in North America: Company Profiles

    6. HPAPI and Cytotoxic Drugs Contract Manufacturers based in Europe: Company Profiles

    7. HPAPI and Cytotoxic Drugs Contract Manufacturers based in Asia Pacific: Company Profiles

    8. Partnerships and Collaborations

    9. Recent Expansions

    10. Capacity Analysis

    11. Market Sizing and Opportunity Analysis

    12. Case-In-Point: Contract Manufacturing of Antibody Drug Conjugates

     

    1. Concluding Remarks

     

    1. Executive Insights

     

    1. Appendix 1: Tabulated Data

     

    1. Appendix 2: List of Companies and Organizations

     

    To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/hpapi-and-cytotoxic-drugs-manufacturing/299.html  

     

    Contact Details

    Gaurav Chaudhary

    +1 (415) 800 3415

    gaurav.chaudhary@rootsanalysis.com  

     


  • Growing at an annualized rate of 12%, the HPAPI and cytotoxic drugs contract

    Roots Analysis has done a detailed study on “HPAPI and Cytotoxic Drugs Manufacturing (3rd Edition) 2020- 2030”, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.

     

    To order this 300+ page report, which features 75+ figures and 150+ tables, please visit this link

     

    Key Market Insights

    • Close to 120 companies across the globe claim to possess the required expertise and infrastructure to offer contract manufacturing services for HPAPIs and cytotoxic drugs
    • The market is fragmented, featuring the presence of both established players and new entrants based in different geographies that claim to be capable of manufacturing highly potent products, at varying scales of operation
    • In order to acquire competencies across the supply chain and cater to evolving needs of sponsors, companies offering services across different scales of operation have established presence in various geographical regions
    • In recent years, a steady increase in partnership activity has been observed in this domain; a variety of deals have been inked related to highly potent drug products
    • In order to enhance the core competencies in this domain, CMOs are actively investing in upgrading existing infrastructure and expanding their respective manufacturing capacities
    • Most of the installed, global HPAPI and cytotoxic drug manufacturing capacity belongs to established CMOs, accounting for close to 75% of the available capacity across various geographies
    • Case-in-point: ADCs represent a significant growth opportunity; over 30 CMOs currently extend their services to manufacture one or multiple components of an ADC molecule
    • We expect highly potent drug developers to continue to outsource their manufacturing operations in the mid to long term, causing service-based revenues to grow at an annualized rate of more than 10%
    • In the long-term, the projected opportunity for the contract manufacturing of HPAPIs and cytotoxic drugs is likely to be well distributed across various dosage forms, nature of molecules and sizes of contract service providers

    For more information, please visit https://www.rootsanalysis.com/reports/view_document/hpapi-and-cytotoxic-drugs-manufacturing/299.html  

     

    Table of Contents

     

    1. PREFACE
      1.1. Scope of the Report
      1.2.       Research Methodology
      1.3.       Chapter Outlines

      2.         EXECUTIVE SUMMARY

      3.         INTRODUCTION
      3.1.       Chapter Overview
      3.2.       Overview of Highly Potent Active Pharmaceutical Ingredients (HPAPIs)
      3.2.1.    Classification based on Potency of Pharmacological Ingredients
      3.2.2.    Types of HPAPIs
      3.2.3.    Challenges Associated with Handling HPAPIs
      3.2.4.    Considerations for Handling HPAPIs
      3.2.5.    Contract Manufacturing of HPAPIs and Cytotoxic Drugs
      3.2.5.1. Selection of a Suitable CMO Partner for HPAPI Manufacturing
      3.2.6.    Regulatory Considerations for HPAPI Manufacturing
      3.2.7.    Concluding Remarks
    2. MARKET LANDSCAPE
      4.1. Chapter Overview
      4.2.       HPAPI and Cytotoxic Drugs Contract Manufacturers: Overall Market Landscape
      4.2.1.    Analysis by Year of Establishment
      4.2.2.    Analysis by Company Size
      4.2.3.    Analysis by Scale of Operation
      4.2.4.    Analysis by Type of Service(s) Offered
      4.2.5.    Analysis by Type of Product
      4.2.6.    Analysis by Type of Pharmacological Molecule
      4.2.7.    Analysis by Location of Headquarters
      4.2.8.    Analysis by Location of Manufacturing Facilities
      4.2.9.    Analysis by Facility Size
      4.2.10. Analysis by Type of Highly Potent Finished Dosage Forms (FDFs)
      4.2.11. Analysis by Type of Primary Packaging

     

    1. COMPANY COMPETITIVE ANALYSIS

    5.1.       Chapter Overview

    5.2.       Methodology

    5.3.       Assumptions and Key Parameters

    5.4.       Company Competitiveness Analysis: HPAPI and Cytotoxic Drugs Contract Manufacturers based     in North America

    5.5.       Company Competitiveness Analysis: HPAPI and Cytotoxic Drugs Contract Manufacturers based in Europe

    5.6.       Company Competitiveness Analysis: HPAPI and Cytotoxic Drugs Contract Manufacturers based in Asia Pacific and Rest of the World

               

    1. HPAPI AND CYTOTOXIC DRUGS CONTRACT MANUFACTURERS BASED IN NORTH AMERICA: COMPANY PROFILES

    6.1.       Chapter Overview

    6.2.       AbbVie Contract Manufacturing

    6.2.1.    Company Overview

    6.2.1.1. HPAPI and Cytotoxic Drugs Manufacturing Service Offerings

    6.2.1.2. Manufacturing Facilities

    6.2.1.3. Recent Developments

    6.2.1.4. Future Outlook

     

    6.3.       Catalent

    6.3.1.    Company Overview

    6.3.1.1. HPAPI and Cytotoxic Drugs Manufacturing Service Offerings

    6.3.1.2. Manufacturing Facilities

    6.3.1.3. Recent Developments

    6.3.1.4. Future Outlook

     

    6.4.       Pfizer CentreOne

    6.4.1.    Company Overview

    6.4.1.1. HPAPI and Cytotoxic Drugs Manufacturing Service Offerings

    6.4.1.2. Manufacturing Facilities

    6.4.1.3. Recent Developments

    6.4.1.4. Future Outlook

     

    6.5.       Piramal Pharma Solutions

    6.5.1.    Company Overview

    6.5.1.1. HPAPI and Cytotoxic Drugs Manufacturing Service Offerings

    6.5.1.2. Manufacturing Facilities

    6.5.1.3. Recent Developments

    6.5.1.4. Future Outlook

     

    6.6.       SAFC (a business division of Sigma-Aldrich)

    6.6.1.    Company Overview

    6.6.1.1. HPAPI and Cytotoxic Drugs Manufacturing Service Offerings

    6.6.1.2. Manufacturing Facilities

    6.6.1.3. Recent Developments

    6.6.1.4. Future Outlook

     

    1. HPAPI AND CYTOTOXIC DRUGS CONTRACT MANUFACTURERS BASED IN EUROPE: COMPANY PROFILES

    7.1.       Chapter Overview

    7.2.       Carbogen Amics

    7.2.1.    Company Overview

    7.2.1.1. HPAPI and Cytotoxic Drugs Manufacturing Service Offerings

    7.2.1.2. Manufacturing Facilities

    7.2.1.3. Recent Developments

    7.2.1.4. Future Outlook

     

    7.3.       Evonik

    7.3.1.    Company Overview

    7.3.1.1. HPAPI and Cytotoxic Drugs Manufacturing Service Offerings

    7.3.1.2. Manufacturing Facilities

    7.3.1.3. Recent Developments

    7.3.1.4. Future Outlook

     

    7.4.       Lonza

    7.4.1.    Company Overview

    7.4.1.1. HPAPI and Cytotoxic Drugs Manufacturing Service Offerings

    7.4.1.2. Manufacturing Facilities

    7.4.1.3. Recent Developments

    7.4.1.4. Future Outlook

     

    7.5.       Siegfried

    7.5.1.    Company Overview

    7.5.1.1. HPAPI and Cytotoxic Drugs Manufacturing Service Offerings

    7.5.1.2. Manufacturing Facilities

    7.5.1.3. Recent Developments

    7.5.1.4. Future Outlook

     

    7.6.       Teva API

    7.6.1.    Company Overview

    7.6.1.1. HPAPI and Cytotoxic Drugs Manufacturing Service Offerings

    7.6.1.2. Manufacturing Facilities

    7.6.1.3. Recent Developments

    7.6.1.4. Future Outlook

     

    1. HPAPI AND CYTOTOXIC DRUGS CONTRACT MANUFACTURERS BASED IN ASIA PACIFIC: COMPANY PROFILES

    8.1.       Chapter Overview

    8.2.       Formosa Laboratories

    8.2.1.    Company Overview

    8.2.1.1. HPAPI and Cytotoxic Drugs Manufacturing Service Offerings

    8.2.1.2. Manufacturing Facilities

    8.2.1.3. Recent Developments

    8.2.1.4. Future Outlook

     

    8.3.       Intas Pharmaceuticals

    8.3.1.    Company Overview

    8.3.1.1. HPAPI and Cytotoxic Drugs Manufacturing Service Offerings

    8.3.1.2. Manufacturing Facilities

    8.3.1.3. Future Outlook

     

    8.4.       MabPlex

    8.4.1.    Company Overview

    8.4.1.1. HPAPI and Cytotoxic Drugs Manufacturing Service Offerings

    8.4.1.2. Manufacturing Facilities

    8.4.1.3. Future Outlook

     

    8.5.       ScinoPharm

    8.5.1.    Company Overview

    8.5.1.1. HPAPIs and Cytotoxic Drugs Manufacturing Service Offerings

    8.5.1.2. Manufacturing Facilities

    8.5.1.3. Future Outlook

     

    8.6.       STA Pharmaceutical (a WuXi AppTec company)

    8.6.1.    Company Overview

    8.6.1.1. HPAPI and Cytotoxic Drugs Manufacturing Service Offerings

    8.6.1.2. Manufacturing Facilities

    8.6.1.3. Recent Developments

    8.6.1.4. Future Outlook

     

    1. PARTNERSHIPS AND COLLABORATIONS

    9.1.       Chapter Overview

    9.2.       Partnership Models

    9.3.       HPAPI and Cytotoxic Drugs Contract Manufacturers: List of Partnerships and Collaborations

    9.3.1.    Analysis by Year of Partnership

    9.3.2.    Analysis by Type of Partnership

    9.3.3.    Analysis by Type of Product

    9.3.4.    Analysis by Scale of Operation

    9.3.5.    Analysis by Company Size

    9.3.6.    Analysis of Acquisitions by Amount Invested

    9.3.7.    Most Active Players: Analysis by Number of Partnerships

    9.3.8.    Geographical Analysis

    9.3.8.1. Continent-wise Distribution

    9.3.8.2. Country-wise Distribution

     

    1. RECENT EXPANSIONS

    10.1.     Chapter Overview

    10.2.     HPAPI and Cytotoxic Drugs Contract Manufacturers: Recent Expansions

    10.2.1.  Analysis by Year of Expansion

    10.2.2.  Analysis by Type of Expansion

    10.2.3.  Analysis by Scale of Operation and Type of Expansion

    10.2.4.  Analysis by Type of Product and Type of Expansion

    10.2.5.  Analysis by Expanded Facility Area

    10.2.6.  Analysis by Amount Invested

    10.2.7.  Analysis by Company Headquarters and Company Size

    10.2.8.  Analysis by Location of Facility and Type of Expansion

    10.2.9.  Most Active Players: Analysis by Number of Expansions

    10.2.10. Geographical Analysis

    10.2.10.1. Continent-wise Distribution

    10.2.10.2. Country-wise Distribution

     

    1. CAPACITY ANALYSIS

    11.1.     Chapter Overview

    11.2.     Key Assumptions and Methodology

    11.3.     HPAPI and Cytotoxic Drugs Contract Manufacturers: Global, Installed Capacity

    11.3.1. Analysis by Company Size

    11.3.2. Analysis by Scale of Operation

    11.3.3. Analysis by Location of Manufacturing Facility

    11.4.     Concluding Remarks

     

    1. MAKE VERSUS BUY DECISION MAKING FRAMEWORK

    12.1.     Chapter Overview

    12.2.     HPAPI and Cytotoxic Drugs Contract Manufacturing: Make versus Buy Decision Making

     

    1. MARKET SIZING AND OPPORTUNITY ANALYSIS

    13.1.     Chapter Overview

    13.2.     Forecast Methodology and Key Assumptions

    13.3.     Overall HPAPI and Cytotoxic Drugs Contract Manufacturing Market, 2020-2030

    13.4.     HPAPI and Cytotoxic Drugs Contract Manufacturing Market, 2020-2030:  Distribution by Type of Product

    13.5.     HPAPI and Cytotoxic Drugs Contract Manufacturing Market, 2020-2030: Distribution by Company Size

    13.6.     HPAPI and Cytotoxic Drugs Contract Manufacturing Market, 2020-2030: Distribution by Scale of Operation

    13.7.     HPAPI and Cytotoxic Drugs Contract Manufacturing Market, 2020-2030: Distribution by Type of Pharmacological Molecule

    13.8.     HPAPI and Cytotoxic Drugs Contract Manufacturing Market, 2020-2030: Distribution by Type of Highly Potent Finished Dosage Forms

    13.9.     HPAPI and Cytotoxic Drugs Contract Manufacturing Market, 2020-2030: Distribution across Key Geographical Regions

    13.9.1.  HPAPI and Cytotoxic Drugs Contract Manufacturing Market in North America, 2020-2030

    13.9.1.1. HPAPI and Cytotoxic Drugs Contract Manufacturing Market in the US, 2020-2030

    13.9.1.2. HPAPI and Cytotoxic Drugs Contract Manufacturing Market in Canada, 2020-2030

    13.9.1.3. HPAPI and Cytotoxic Drugs Contract Manufacturing Market in Mexico, 2020-2030

    13.9.2.  HPAPI and Cytotoxic Drugs Contract Manufacturing Market in Europe, 2020-2030

    13.9.2.1. HPAPI and Cytotoxic Drugs Contract Manufacturing Market in the UK, 2020-2030

    13.9.2.2. HPAPI and Cytotoxic Drugs Contract Manufacturing Market in Italy, 2020-2030

    13.9.2.3. HPAPI and Cytotoxic Drugs Contract Manufacturing Market in Germany, 2020-2030

    13.9.2.4. HPAPI and Cytotoxic Drugs Contract Manufacturing Market in France, 2020-2030

    13.8.2.5. HPAPI and Cytotoxic Drugs Contract Manufacturing Market in Spain, 2020-2030

    13.9.2.6. HPAPI and Cytotoxic Drugs Contract Manufacturing Market in Rest of Europe, 2020-2030

    13.9.3.    HPAPI and Cytotoxic Drugs Contract Manufacturing Market in Asia Pacific, 2020-2030 (USD Billion)

    13.9.3.1. HPAPI and Cytotoxic Drugs Contract Manufacturing Market in China, 2020-2030

    13.9.3.2. HPAPI and Cytotoxic Drugs Contract Manufacturing Market in India, 2020-2030

    13.9.3.3. HPAPI and Cytotoxic Drugs Contract Manufacturing Market in Rest of Asia Pacific, 2020-2030

    13.9.4.  HPAPI and Cytotoxic Drugs Contract Manufacturing Market in the Rest of the World, 2020-2030

     

    1. SWOT ANALYSIS

    14.1.     Chapter Overview

    14.2.     Strengths

    14.3.     Weaknesses

    14.4.     Opportunities

    14.5.     Threats

    14.6.     Concluding Remarks

     

    1. CASE-IN-POINT: CONTRACT MANUFACTURING OF ANTIBODY DRUG CONJUGATES

    15.1.     Chapter Overview

    15.2.     Key Components of ADCs

    15.2.1.  Antibody

    15.2.2.  Cytotoxin

    15.2.3.  Linker

    15.3.     Overview of ADC Manufacturing

    15.3.1.  Key Process Steps

    15.3.2.  Challenges Associated with ADC Manufacturing

    15.3.3.  Growing Trend of Outsourcing in ADC Manufacturing

    15.4.     Challenges Associated with Supply Chain and Method Transfer

    15.5.     Growing Demand for One-Stop-Shops and Integrated Service Providers

    15.6.     Key Considerations for Selecting a CMO Partner

    15.7.     ADC Contract Manufacturers: Overall Market Landscape

    15.7.1.  Analysis by Location of Headquarters

    15.7.2.  Analysis by Year of Establishment

    15.7.3.  Analysis by Company Size

    15.7.4.  Analysis by Service(s) Offered

    15.7.5.  Analysis by Location of Headquarters

    15.7.5.  Analysis by Location of Manufacturing Facility

    15.7.6.  Analysis by Scale of Operation

     

    1. CONCLUDING REMARKS

     

    1. EXECUTIVE INSIGHTS

    17.1.     Chapter Overview

     

    17.2.     BSP Pharmaceuticals

    17.2.1.  Company Snapshot

    17.2.2.  Interview Transcript: Antonella Mancuso and Maria Elena Guadagno, Vice President and Chief Operating Officer and Business Director

     

    17.3.     Catalent

    17.3.1.  Company Snapshot

    17.3.2.  Interview Transcript: Stacy McDonald and Jennifer L. Mitcham, Group Product Manager and Director-Business Development

     

    17.4.     CordenPharma

    17.4.1.  Company Snapshot

    17.4.2.  Interview Transcript: Roberto Margarita, Business Development Director

     

    17.5.     Helsinn

    17.5.1.  Company Snapshot

    17.5.2.  Interview Transcript: Allison Vavala, Senior Manager, Business Development

     

    17.6.     Idifarma

    17.6.1.  Company Snapshot

    17.6.2.  Interview Transcript: Javier E. Aznárez Araiz, Business Development

     

    17.7.     Piramal Healthcare

    17.7.1.  Company Snapshot

    17.7.2.  Interview Transcript: Dr. Mark Wright, Site Head, Grangemouth

     

    17.8      ProJect Pharmaceutics

    17.8.1.  Company Snapshot

    17.8.2.  Interview Transcript: Klaus Hellerbrand, Managing Director

     

    17.9.     Alphora Research

    17.9.1.  Company Snapshot

    17.9.2.  Interview Transcript: Kevin Rosenthal, Business Head, Formulations and Finished Products

     

    1. APPENDIX 1: TABULATED DATA

     

    1. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

     

    Contact Details

    Gaurav Chaudhary

    +1 (415) 800 3415

    gaurav.chaudhary@rootsanalysis.com


  • Growing at an annualized rate of 12%, the HPAPI and cytotoxic drugs contract

    Roots Analysis has done a detailed study on “HPAPI and Cytotoxic Drugs Manufacturing (3rd Edition) 2020- 2030”, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.

     

    To order this 300+ page report, which features 75+ figures and 150+ tables, please visit this link

     

    Key Market Insights

    • Close to 120 companies across the globe claim to possess the required expertise and infrastructure to offer contract manufacturing services for HPAPIs and cytotoxic drugs
    • The market is fragmented, featuring the presence of both established players and new entrants based in different geographies that claim to be capable of manufacturing highly potent products, at varying scales of operation
    • In order to acquire competencies across the supply chain and cater to evolving needs of sponsors, companies offering services across different scales of operation have established presence in various geographical regions
    • In recent years, a steady increase in partnership activity has been observed in this domain; a variety of deals have been inked related to highly potent drug products
    • In order to enhance the core competencies in this domain, CMOs are actively investing in upgrading existing infrastructure and expanding their respective manufacturing capacities
    • Most of the installed, global HPAPI and cytotoxic drug manufacturing capacity belongs to established CMOs, accounting for close to 75% of the available capacity across various geographies
    • Case-in-point: ADCs represent a significant growth opportunity; over 30 CMOs currently extend their services to manufacture one or multiple components of an ADC molecule
    • We expect highly potent drug developers to continue to outsource their manufacturing operations in the mid to long term, causing service-based revenues to grow at an annualized rate of more than 10%
    • In the long-term, the projected opportunity for the contract manufacturing of HPAPIs and cytotoxic drugs is likely to be well distributed across various dosage forms, nature of molecules and sizes of contract service providers

    For more information, please visit https://www.rootsanalysis.com/reports/view_document/hpapi-and-cytotoxic-drugs-manufacturing/299.html  

     

    Table of Contents

     

    1. PREFACE
      1.1. Scope of the Report
      1.2.       Research Methodology
      1.3.       Chapter Outlines

      2.         EXECUTIVE SUMMARY

      3.         INTRODUCTION
      3.1.       Chapter Overview
      3.2.       Overview of Highly Potent Active Pharmaceutical Ingredients (HPAPIs)
      3.2.1.    Classification based on Potency of Pharmacological Ingredients
      3.2.2.    Types of HPAPIs
      3.2.3.    Challenges Associated with Handling HPAPIs
      3.2.4.    Considerations for Handling HPAPIs
      3.2.5.    Contract Manufacturing of HPAPIs and Cytotoxic Drugs
      3.2.5.1. Selection of a Suitable CMO Partner for HPAPI Manufacturing
      3.2.6.    Regulatory Considerations for HPAPI Manufacturing
      3.2.7.    Concluding Remarks
    2. MARKET LANDSCAPE
      4.1. Chapter Overview
      4.2.       HPAPI and Cytotoxic Drugs Contract Manufacturers: Overall Market Landscape
      4.2.1.    Analysis by Year of Establishment
      4.2.2.    Analysis by Company Size
      4.2.3.    Analysis by Scale of Operation
      4.2.4.    Analysis by Type of Service(s) Offered
      4.2.5.    Analysis by Type of Product
      4.2.6.    Analysis by Type of Pharmacological Molecule
      4.2.7.    Analysis by Location of Headquarters
      4.2.8.    Analysis by Location of Manufacturing Facilities
      4.2.9.    Analysis by Facility Size
      4.2.10. Analysis by Type of Highly Potent Finished Dosage Forms (FDFs)
      4.2.11. Analysis by Type of Primary Packaging

     

    1. COMPANY COMPETITIVE ANALYSIS

    5.1.       Chapter Overview

    5.2.       Methodology

    5.3.       Assumptions and Key Parameters

    5.4.       Company Competitiveness Analysis: HPAPI and Cytotoxic Drugs Contract Manufacturers based     in North America

    5.5.       Company Competitiveness Analysis: HPAPI and Cytotoxic Drugs Contract Manufacturers based in Europe

    5.6.       Company Competitiveness Analysis: HPAPI and Cytotoxic Drugs Contract Manufacturers based in Asia Pacific and Rest of the World

               

    1. HPAPI AND CYTOTOXIC DRUGS CONTRACT MANUFACTURERS BASED IN NORTH AMERICA: COMPANY PROFILES

    6.1.       Chapter Overview

    6.2.       AbbVie Contract Manufacturing

    6.2.1.    Company Overview

    6.2.1.1. HPAPI and Cytotoxic Drugs Manufacturing Service Offerings

    6.2.1.2. Manufacturing Facilities

    6.2.1.3. Recent Developments

    6.2.1.4. Future Outlook

     

    6.3.       Catalent

    6.3.1.    Company Overview

    6.3.1.1. HPAPI and Cytotoxic Drugs Manufacturing Service Offerings

    6.3.1.2. Manufacturing Facilities

    6.3.1.3. Recent Developments

    6.3.1.4. Future Outlook

     

    6.4.       Pfizer CentreOne

    6.4.1.    Company Overview

    6.4.1.1. HPAPI and Cytotoxic Drugs Manufacturing Service Offerings

    6.4.1.2. Manufacturing Facilities

    6.4.1.3. Recent Developments

    6.4.1.4. Future Outlook

     

    6.5.       Piramal Pharma Solutions

    6.5.1.    Company Overview

    6.5.1.1. HPAPI and Cytotoxic Drugs Manufacturing Service Offerings

    6.5.1.2. Manufacturing Facilities

    6.5.1.3. Recent Developments

    6.5.1.4. Future Outlook

     

    6.6.       SAFC (a business division of Sigma-Aldrich)

    6.6.1.    Company Overview

    6.6.1.1. HPAPI and Cytotoxic Drugs Manufacturing Service Offerings

    6.6.1.2. Manufacturing Facilities

    6.6.1.3. Recent Developments

    6.6.1.4. Future Outlook

     

    1. HPAPI AND CYTOTOXIC DRUGS CONTRACT MANUFACTURERS BASED IN EUROPE: COMPANY PROFILES

    7.1.       Chapter Overview

    7.2.       Carbogen Amics

    7.2.1.    Company Overview

    7.2.1.1. HPAPI and Cytotoxic Drugs Manufacturing Service Offerings

    7.2.1.2. Manufacturing Facilities

    7.2.1.3. Recent Developments

    7.2.1.4. Future Outlook

     

    7.3.       Evonik

    7.3.1.    Company Overview

    7.3.1.1. HPAPI and Cytotoxic Drugs Manufacturing Service Offerings

    7.3.1.2. Manufacturing Facilities

    7.3.1.3. Recent Developments

    7.3.1.4. Future Outlook

     

    7.4.       Lonza

    7.4.1.    Company Overview

    7.4.1.1. HPAPI and Cytotoxic Drugs Manufacturing Service Offerings

    7.4.1.2. Manufacturing Facilities

    7.4.1.3. Recent Developments

    7.4.1.4. Future Outlook

     

    7.5.       Siegfried

    7.5.1.    Company Overview

    7.5.1.1. HPAPI and Cytotoxic Drugs Manufacturing Service Offerings

    7.5.1.2. Manufacturing Facilities

    7.5.1.3. Recent Developments

    7.5.1.4. Future Outlook

     

    7.6.       Teva API

    7.6.1.    Company Overview

    7.6.1.1. HPAPI and Cytotoxic Drugs Manufacturing Service Offerings

    7.6.1.2. Manufacturing Facilities

    7.6.1.3. Recent Developments

    7.6.1.4. Future Outlook

     

    1. HPAPI AND CYTOTOXIC DRUGS CONTRACT MANUFACTURERS BASED IN ASIA PACIFIC: COMPANY PROFILES

    8.1.       Chapter Overview

    8.2.       Formosa Laboratories

    8.2.1.    Company Overview

    8.2.1.1. HPAPI and Cytotoxic Drugs Manufacturing Service Offerings

    8.2.1.2. Manufacturing Facilities

    8.2.1.3. Recent Developments

    8.2.1.4. Future Outlook

     

    8.3.       Intas Pharmaceuticals

    8.3.1.    Company Overview

    8.3.1.1. HPAPI and Cytotoxic Drugs Manufacturing Service Offerings

    8.3.1.2. Manufacturing Facilities

    8.3.1.3. Future Outlook

     

    8.4.       MabPlex

    8.4.1.    Company Overview

    8.4.1.1. HPAPI and Cytotoxic Drugs Manufacturing Service Offerings

    8.4.1.2. Manufacturing Facilities

    8.4.1.3. Future Outlook

     

    8.5.       ScinoPharm

    8.5.1.    Company Overview

    8.5.1.1. HPAPIs and Cytotoxic Drugs Manufacturing Service Offerings

    8.5.1.2. Manufacturing Facilities

    8.5.1.3. Future Outlook

     

    8.6.       STA Pharmaceutical (a WuXi AppTec company)

    8.6.1.    Company Overview

    8.6.1.1. HPAPI and Cytotoxic Drugs Manufacturing Service Offerings

    8.6.1.2. Manufacturing Facilities

    8.6.1.3. Recent Developments

    8.6.1.4. Future Outlook

     

    1. PARTNERSHIPS AND COLLABORATIONS

    9.1.       Chapter Overview

    9.2.       Partnership Models

    9.3.       HPAPI and Cytotoxic Drugs Contract Manufacturers: List of Partnerships and Collaborations

    9.3.1.    Analysis by Year of Partnership

    9.3.2.    Analysis by Type of Partnership

    9.3.3.    Analysis by Type of Product

    9.3.4.    Analysis by Scale of Operation

    9.3.5.    Analysis by Company Size

    9.3.6.    Analysis of Acquisitions by Amount Invested

    9.3.7.    Most Active Players: Analysis by Number of Partnerships

    9.3.8.    Geographical Analysis

    9.3.8.1. Continent-wise Distribution

    9.3.8.2. Country-wise Distribution

     

    1. RECENT EXPANSIONS

    10.1.     Chapter Overview

    10.2.     HPAPI and Cytotoxic Drugs Contract Manufacturers: Recent Expansions

    10.2.1.  Analysis by Year of Expansion

    10.2.2.  Analysis by Type of Expansion

    10.2.3.  Analysis by Scale of Operation and Type of Expansion

    10.2.4.  Analysis by Type of Product and Type of Expansion

    10.2.5.  Analysis by Expanded Facility Area

    10.2.6.  Analysis by Amount Invested

    10.2.7.  Analysis by Company Headquarters and Company Size

    10.2.8.  Analysis by Location of Facility and Type of Expansion

    10.2.9.  Most Active Players: Analysis by Number of Expansions

    10.2.10. Geographical Analysis

    10.2.10.1. Continent-wise Distribution

    10.2.10.2. Country-wise Distribution

     

    1. CAPACITY ANALYSIS

    11.1.     Chapter Overview

    11.2.     Key Assumptions and Methodology

    11.3.     HPAPI and Cytotoxic Drugs Contract Manufacturers: Global, Installed Capacity

    11.3.1. Analysis by Company Size

    11.3.2. Analysis by Scale of Operation

    11.3.3. Analysis by Location of Manufacturing Facility

    11.4.     Concluding Remarks

     

    1. MAKE VERSUS BUY DECISION MAKING FRAMEWORK

    12.1.     Chapter Overview

    12.2.     HPAPI and Cytotoxic Drugs Contract Manufacturing: Make versus Buy Decision Making

     

    1. MARKET SIZING AND OPPORTUNITY ANALYSIS

    13.1.     Chapter Overview

    13.2.     Forecast Methodology and Key Assumptions

    13.3.     Overall HPAPI and Cytotoxic Drugs Contract Manufacturing Market, 2020-2030

    13.4.     HPAPI and Cytotoxic Drugs Contract Manufacturing Market, 2020-2030:  Distribution by Type of Product

    13.5.     HPAPI and Cytotoxic Drugs Contract Manufacturing Market, 2020-2030: Distribution by Company Size

    13.6.     HPAPI and Cytotoxic Drugs Contract Manufacturing Market, 2020-2030: Distribution by Scale of Operation

    13.7.     HPAPI and Cytotoxic Drugs Contract Manufacturing Market, 2020-2030: Distribution by Type of Pharmacological Molecule

    13.8.     HPAPI and Cytotoxic Drugs Contract Manufacturing Market, 2020-2030: Distribution by Type of Highly Potent Finished Dosage Forms

    13.9.     HPAPI and Cytotoxic Drugs Contract Manufacturing Market, 2020-2030: Distribution across Key Geographical Regions

    13.9.1.  HPAPI and Cytotoxic Drugs Contract Manufacturing Market in North America, 2020-2030

    13.9.1.1. HPAPI and Cytotoxic Drugs Contract Manufacturing Market in the US, 2020-2030

    13.9.1.2. HPAPI and Cytotoxic Drugs Contract Manufacturing Market in Canada, 2020-2030

    13.9.1.3. HPAPI and Cytotoxic Drugs Contract Manufacturing Market in Mexico, 2020-2030

    13.9.2.  HPAPI and Cytotoxic Drugs Contract Manufacturing Market in Europe, 2020-2030

    13.9.2.1. HPAPI and Cytotoxic Drugs Contract Manufacturing Market in the UK, 2020-2030

    13.9.2.2. HPAPI and Cytotoxic Drugs Contract Manufacturing Market in Italy, 2020-2030

    13.9.2.3. HPAPI and Cytotoxic Drugs Contract Manufacturing Market in Germany, 2020-2030

    13.9.2.4. HPAPI and Cytotoxic Drugs Contract Manufacturing Market in France, 2020-2030

    13.8.2.5. HPAPI and Cytotoxic Drugs Contract Manufacturing Market in Spain, 2020-2030

    13.9.2.6. HPAPI and Cytotoxic Drugs Contract Manufacturing Market in Rest of Europe, 2020-2030

    13.9.3.    HPAPI and Cytotoxic Drugs Contract Manufacturing Market in Asia Pacific, 2020-2030 (USD Billion)

    13.9.3.1. HPAPI and Cytotoxic Drugs Contract Manufacturing Market in China, 2020-2030

    13.9.3.2. HPAPI and Cytotoxic Drugs Contract Manufacturing Market in India, 2020-2030

    13.9.3.3. HPAPI and Cytotoxic Drugs Contract Manufacturing Market in Rest of Asia Pacific, 2020-2030

    13.9.4.  HPAPI and Cytotoxic Drugs Contract Manufacturing Market in the Rest of the World, 2020-2030

     

    1. SWOT ANALYSIS

    14.1.     Chapter Overview

    14.2.     Strengths

    14.3.     Weaknesses

    14.4.     Opportunities

    14.5.     Threats

    14.6.     Concluding Remarks

     

    1. CASE-IN-POINT: CONTRACT MANUFACTURING OF ANTIBODY DRUG CONJUGATES

    15.1.     Chapter Overview

    15.2.     Key Components of ADCs

    15.2.1.  Antibody

    15.2.2.  Cytotoxin

    15.2.3.  Linker

    15.3.     Overview of ADC Manufacturing

    15.3.1.  Key Process Steps

    15.3.2.  Challenges Associated with ADC Manufacturing

    15.3.3.  Growing Trend of Outsourcing in ADC Manufacturing

    15.4.     Challenges Associated with Supply Chain and Method Transfer

    15.5.     Growing Demand for One-Stop-Shops and Integrated Service Providers

    15.6.     Key Considerations for Selecting a CMO Partner

    15.7.     ADC Contract Manufacturers: Overall Market Landscape

    15.7.1.  Analysis by Location of Headquarters

    15.7.2.  Analysis by Year of Establishment

    15.7.3.  Analysis by Company Size

    15.7.4.  Analysis by Service(s) Offered

    15.7.5.  Analysis by Location of Headquarters

    15.7.5.  Analysis by Location of Manufacturing Facility

    15.7.6.  Analysis by Scale of Operation

     

    1. CONCLUDING REMARKS

     

    1. EXECUTIVE INSIGHTS

    17.1.     Chapter Overview

     

    17.2.     BSP Pharmaceuticals

    17.2.1.  Company Snapshot

    17.2.2.  Interview Transcript: Antonella Mancuso and Maria Elena Guadagno, Vice President and Chief Operating Officer and Business Director

     

    17.3.     Catalent

    17.3.1.  Company Snapshot

    17.3.2.  Interview Transcript: Stacy McDonald and Jennifer L. Mitcham, Group Product Manager and Director-Business Development

     

    17.4.     CordenPharma

    17.4.1.  Company Snapshot

    17.4.2.  Interview Transcript: Roberto Margarita, Business Development Director

     

    17.5.     Helsinn

    17.5.1.  Company Snapshot

    17.5.2.  Interview Transcript: Allison Vavala, Senior Manager, Business Development

     

    17.6.     Idifarma

    17.6.1.  Company Snapshot

    17.6.2.  Interview Transcript: Javier E. Aznárez Araiz, Business Development

     

    17.7.     Piramal Healthcare

    17.7.1.  Company Snapshot

    17.7.2.  Interview Transcript: Dr. Mark Wright, Site Head, Grangemouth

     

    17.8      ProJect Pharmaceutics

    17.8.1.  Company Snapshot

    17.8.2.  Interview Transcript: Klaus Hellerbrand, Managing Director

     

    17.9.     Alphora Research

    17.9.1.  Company Snapshot

    17.9.2.  Interview Transcript: Kevin Rosenthal, Business Head, Formulations and Finished Products

     

    1. APPENDIX 1: TABULATED DATA

     

    1. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

     

    Contact Details

    Gaurav Chaudhary

    +1 (415) 800 3415

    gaurav.chaudhary@rootsanalysis.com


  • Growing at an annualized rate of 12%, the HPAPI and cytotoxic drugs contract

    Manufacturing highly potent drug products is technically and financially demanding; as a result, drug manufacturers are becoming increasingly reliant on contract service providers

     

    Roots Analysis is pleased to announce the publication of its recent study, titled, “HPAPI and Cytotoxic Drugs Manufacturing (3rd Edition) 2020-2030.”

     

    The report features an extensive study of the current market landscape and future opportunities associated with the contract manufacturing of HPAPIs and cytotoxic drugs. The study also features a detailed analysis of the key drivers and trends related to this evolving domain. In addition to other elements, the study includes:

    • A detailed assessment of the current market landscape of companies offering contract services for manufacturing HPAPIs and cytotoxic drugs.
    • A competitiveness analysis of HPAPI and cytotoxic drugs contract manufacturers, featuring insightful representations.
    • Detailed profiles of leading contract manufacturers of HPAPI and cytotoxic drugs (shortlisted on the basis of proprietary criterion).
    • An analysis of the partnerships that have been established in this domain, in the recent past.
    • An analysis of the various expansion initiatives undertaken by the players in this domain.
    • An estimate of the overall, installed capacity for manufacturing HPAPIs and cytotoxic drugs based on data reported by industry stakeholders in the public domain.
    • A qualitative analysis to decide whether to manufacture the potent products in-house or engage the services of a CMO.
    • A discussion on affiliated trends, key drivers and challenges which are likely to impact the industry’s evolution.
    • A case study on the antibody drug conjugates (ADCs) manufacturing market, highlighting a list of contract service providers and in-house manufacturers in this domain.
    • A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
      • Type of Product
    • HPAPIs
    • Highly Potent Finished Dosage Forms

     

    • Company Size
    • Small-sized
    • Mid-sized
    • Large / Very Large

     

    • Scale of Operation
    • Preclinical / Clinical
    • Commercial

     

    • Type of Pharmacological Molecule
    • Small Molecules
    • Biologics

     

    • Type of Highly Potent Finished Dosage Form
    • Injectables
    • Oral Solids
    • Creams
    • Others
      • Key geographical regions
    • North America
    • Europe
    • Asia Pacific
    • Rest of the World

     

    The report includes detailed transcripts of discussions held with the following senior level representatives of stakeholder companies:

    • Antonella Mancuso (Vice President and Chief Operating Officer, BSP Pharmaceuticals) and Maria Elena Guadagno (Business Director, BSP Pharmaceuticals)
    • Klaus Hellerbrand (Managing Director, ProJect Pharmaceutics)
    • Kevin Rosenthal (Business Head, Formulations and Finished Products, Alphora Research)
    • Jennifer L Mitcham (Director, Business Development, Catalent Pharma Solutions) and Stacy McDonald (Group Product Manager, Catalent Pharma Solutions)
    • Roberto Margarita (Business Development Director, CordenPharma)
    • Allison Vavala (Senior Manager, Business Development, Helsinn)
    • Mark Wright (Site Head, Piramal Healthcare)
    • Javier E. Aznárez Araiz (Business Development Technician, Idifarma)

     

    Key companies covered in the report

    • AbbVie Contract Manufacturing
    • CARBOGEN AMCIS
    • Catalent
    • Evonik
    • Formosa Laboratories
    • Intas
    • Lonza
    • MabPlex
    • Pfizer CentreOne

     

    For more information please click on the following link:

    https://www.rootsanalysis.com/reports/view_document/hpapi-and-cytotoxic-drugs-manufacturing/299.html  

     

    Other Recent Offerings

    1. Antibody Contract Manufacturing Market, 2020 – 2030
    2. Cell Therapy Manufacturing Market (3rd Edition), 2019 – 2030
    3. Biopharma Contract Manufacturing Market (3rd Edition), 2019 – 2030

     

    About Roots Analysis

    Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

     

    Contact Information

    Roots Analysis Private Limited

    Gaurav Chaudhary

    +1 (415) 800 3415

    gaurav.chaudhary@rootsanalysis.com

     

     


  • Growing at an annualized rate of 12%, the HPAPI and cytotoxic drugs contract

    Manufacturing highly potent drug products is technically and financially demanding; as a result, drug manufacturers are becoming increasingly reliant on contract service providers

     

    Roots Analysis is pleased to announce the publication of its recent study, titled, “HPAPI and Cytotoxic Drugs Manufacturing (3rd Edition) 2020-2030.”

     

    The report features an extensive study of the current market landscape and future opportunities associated with the contract manufacturing of HPAPIs and cytotoxic drugs. The study also features a detailed analysis of the key drivers and trends related to this evolving domain. In addition to other elements, the study includes:

    • A detailed assessment of the current market landscape of companies offering contract services for manufacturing HPAPIs and cytotoxic drugs.
    • A competitiveness analysis of HPAPI and cytotoxic drugs contract manufacturers, featuring insightful representations.
    • Detailed profiles of leading contract manufacturers of HPAPI and cytotoxic drugs (shortlisted on the basis of proprietary criterion).
    • An analysis of the partnerships that have been established in this domain, in the recent past.
    • An analysis of the various expansion initiatives undertaken by the players in this domain.
    • An estimate of the overall, installed capacity for manufacturing HPAPIs and cytotoxic drugs based on data reported by industry stakeholders in the public domain.
    • A qualitative analysis to decide whether to manufacture the potent products in-house or engage the services of a CMO.
    • A discussion on affiliated trends, key drivers and challenges which are likely to impact the industry’s evolution.
    • A case study on the antibody drug conjugates (ADCs) manufacturing market, highlighting a list of contract service providers and in-house manufacturers in this domain.
    • A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
      • Type of Product
    • HPAPIs
    • Highly Potent Finished Dosage Forms

     

    • Company Size
    • Small-sized
    • Mid-sized
    • Large / Very Large

     

    • Scale of Operation
    • Preclinical / Clinical
    • Commercial

     

    • Type of Pharmacological Molecule
    • Small Molecules
    • Biologics

     

    • Type of Highly Potent Finished Dosage Form
    • Injectables
    • Oral Solids
    • Creams
    • Others
      • Key geographical regions
    • North America
    • Europe
    • Asia Pacific
    • Rest of the World

     

    The report includes detailed transcripts of discussions held with the following senior level representatives of stakeholder companies:

    • Antonella Mancuso (Vice President and Chief Operating Officer, BSP Pharmaceuticals) and Maria Elena Guadagno (Business Director, BSP Pharmaceuticals)
    • Klaus Hellerbrand (Managing Director, ProJect Pharmaceutics)
    • Kevin Rosenthal (Business Head, Formulations and Finished Products, Alphora Research)
    • Jennifer L Mitcham (Director, Business Development, Catalent Pharma Solutions) and Stacy McDonald (Group Product Manager, Catalent Pharma Solutions)
    • Roberto Margarita (Business Development Director, CordenPharma)
    • Allison Vavala (Senior Manager, Business Development, Helsinn)
    • Mark Wright (Site Head, Piramal Healthcare)
    • Javier E. Aznárez Araiz (Business Development Technician, Idifarma)

     

    Key companies covered in the report

    • AbbVie Contract Manufacturing
    • CARBOGEN AMCIS
    • Catalent
    • Evonik
    • Formosa Laboratories
    • Intas
    • Lonza
    • MabPlex
    • Pfizer CentreOne

     

    For more information please click on the following link:

    https://www.rootsanalysis.com/reports/view_document/hpapi-and-cytotoxic-drugs-manufacturing/299.html  

     

    Other Recent Offerings

    1. Antibody Contract Manufacturing Market, 2020 – 2030
    2. Cell Therapy Manufacturing Market (3rd Edition), 2019 – 2030
    3. Biopharma Contract Manufacturing Market (3rd Edition), 2019 – 2030

     

    About Roots Analysis

    Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

     

    Contact Information

    Roots Analysis Private Limited

    Gaurav Chaudhary

    +1 (415) 800 3415

    gaurav.chaudhary@rootsanalysis.com

     

     


  • The continuous manufacturing market is projected to grow at an annualized rate of over 15%

    Roots Analysis has done a detailed study on Continuous Manufacturing Market (Small Molecules and Biologics), 2020 – 2030, covering key aspects of the industry and identifying future growth opportunities.

     

    To order this 310+ page report, which features 110+ figures and 200+ tables, please visit this link

     

    Key Market Insights

    • Eminent representatives from prominent contract service provider companies / organizations are both optimistic and cautious regarding the rising interest in continuous flow technologies, and its adoption
    • Over 60 companies across the globe claim to manufacture drug products / drug substances using the continuous manufacturing technique, either for in-house requirements or for contract service engagements
    • The market landscape features the presence of several well-established players, most of which claim to manufacture small molecules via the continuous technique, and are based in the developed geographies
    • Companies have established continuous drug manufacturing facilities for diverse types of dosage forms in various geographies; Europe and North America have emerged as the key hubs for these facilities
    • Several patents have been filed / granted specifically related to continuous manufacturing of pharmaceutical substances, both industry and non-industry players are actively involved in such efforts
    • Organizations have also extended financial support to aid the research efforts being put by various stakeholders in this domain; the current focus is on investigation of continuous manufacturing technologies
    • Over time, there has been a lot of activity in this arena, including the establishment of several partnerships and investments in capability and capacity expansions and new facilities worldwide
    • Most of the continuous manufacturing capacity belongs to established companies (in-house manufacturers and CMOs), accounting for over 70% of the available capacity across various geographies
    • Involvement of various other stakeholders including continuous equipment providers and modular facility providers is likely to revolutionize the overall manufacturing domain
    • As the adoption of continuous manufacturing technologies increases, the market is likely to witness significant growth; in the short term, majority of service-based revenues is likely to come from drug product related projects

     

    For more information, please visit https://www.rootsanalysis.com/reports/view_document/continuous-manufacturing/308.html

     

    Table of Contents

     

    TABLE OF CONTENTS

     

    1. PREFACE

    1.1.       Scope of the Report

    1.2.       Research Methodology

    1.3.       Chapter Outlines

     

    1. EXECUTIVE SUMMARY

     

    1. INTRODUCTION

    3.1.       Chapter Overview

    3.2.       Historical Evolution of Continuous Manufacturing

    3.3.       Continuous Manufacturing in the Pharmaceutical Industry

    3.3.1.    Regulatory Landscape

    3.3.2.    Early Adopters of Continuous Manufacturing

    3.3.3.    Anticipated Shift to Continuous Manufacturing

    3.3.4.    Advantages of Continuous Manufacturing

    3.3.5.    Key Challenges Associated with Continuous Manufacturing

    3.3.6.    Future Perspectives

     

    1. MARKET LANDSCAPE

    4.1.       Chapter Overview

    4.2.       Companies with Expertise in Continuous Manufacturing: Overall Market Landscape

    4.2.1.    Analysis by Year of Establishment

    4.2.2.    Analysis by Company Size

    4.2.3.    Analysis by Purpose of Manufacturing

    4.2.4.    Analysis by Scale of Operation

    4.2.5.    Analysis by Location of Headquarters

    4.2.6.    Analysis by Location of Continuous Manufacturing Facilities

    4.2.7.    Analysis by Type of Drug Molecule

    4.2.8.    Analysis by Type of Continuous Manufacturing Related Service

    4.2.9.    Analysis by Type of Dosage Form

    4.2.10.  Heat Map: Analysis by Company Size and Location of Headquarters

    4.2.11.  Information on Production Capacity

    4.2.12.  Logo Landscape: Analysis by Year of Establishment and Company Size 

    4.2.13.  Grid Representation: Analysis by Scale of Operation, Type of Continuous Manufacturing Related Service and Type of Dosage Form

    4.2.14.  Geographical Map: Analysis by Location of Continuous Manufacturing Facilities and Type of Drug Molecule

     

    1. COMPANIES WITH EXPERTISE IN CONTINUOUS MANUFACTURING IN NORTH AMERICA: PROFILES

    5.1.       Chapter Overview

    5.2.       AbbVie Contract Manufacturing

    5.2.1.    Company Overview

    5.2.2.    Service Portfolio

    5.2.3.    Continuous Manufacturing Capabilities and Facilities

    5.2.4.    Recent Developments and Future Outlook

     

    5.3.       Cambrex

    5.3.1.    Company Overview

    5.3.2.    Service Portfolio

    5.3.3.    Continuous Manufacturing Capabilities and Facilities

    5.3.4.    Recent Developments and Future Outlook

     

    5.4.       Patheon

    5.4.1.    Company Overview

    5.4.2.    Service Portfolio

    5.4.3.    Continuous Manufacturing Capabilities and Facilities

    5.4.4.    Recent Developments and Future Outlook

     

    5.5.       SK biotek

    5.5.1.    Company Overview

    5.5.2.    Service Portfolio

    5.5.3.    Continuous Manufacturing Capabilities and Facilities

    5.5.4.    Recent Developments and Future Outlook

     

    1. COMPANIES WITH EXPERTISE IN CONTINUOUS MANUFACTURING IN EUROPE: PROFILES

    6.1.       Chapter Overview

    6.2.       Ajinomoto Bio-Pharma Services

    6.2.1.    Company Overview

    6.2.2.    Service Portfolio

    6.2.3.    Continuous Manufacturing Capabilities and Facilities

    6.2.4.    Recent Developments and Future Outlook

     

    6.3.       Almac

    6.3.1.    Company Overview

    6.3.2.    Service Portfolio

    6.3.3.    Continuous Manufacturing Capabilities and Facilities

    6.3.4.    Recent Developments and Future Outlook

     

    6.4.       Boehringer Ingelheim BioXcellence™

    6.4.1.    Company Overview

    6.4.2.    Service Portfolio

    6.4.3.    Continuous Manufacturing Capabilities and Facilities

    6.4.4.    Recent Developments and Future Outlook

     

    6.5.       CordonPharma

    6.5.1.    Company Overview

    6.5.2.    Service Portfolio

    6.5.3.    Continuous Manufacturing Capabilities and Facilities

    6.5.4.    Recent Developments and Future Outlook

     

    6.6.       Hovione

    6.6.1.    Company Overview

    6.6.2.    Service Portfolio

    6.6.3.    Continuous Manufacturing Capabilities and Facilities

    6.6.4.    Recent Developments and Future Outlook

     

    6.7.       Lonza

    6.7.1.    Company Overview

    6.7.2.    Service Portfolio

    6.7.3.    Continuous Manufacturing Capabilities and Facilities

    6.7.4.    Recent Developments and Future Outlook

     

    1. COMPANIES WITH EXPERTISE IN CONTINUOUS MANUFACTURING IN ASIA-PACIFIC: PROFILES

    7.1.       Chapter Overview

    7.2.       Kaneka

    7.2.1.    Company Overview

    7.2.2.    Service Portfolio

    7.2.3.    Continuous Manufacturing Capabilities and Facilities

    7.2.4.    Recent Developments and Future Outlook     

     

    7.3.       WuXi AppTec

    7.3.1.    Company Overview

    7.3.2.    Service Portfolio

    7.3.3.    Continuous Manufacturing Capabilities and Facilities

    7.3.4.    Recent Developments and Future Outlook                 

     

    1. RECENT PARTNERSHIPS AND COLLABORATIONS

    8.1.       Chapter Overview

    8.2.       Partnership Models

    8.3.       List of Partnerships and Collaborations

    8.3.1.    Analysis by Year of Partnership

    8.3.2.    Analysis by Type of Partnership

    8.3.3.    Analysis by Scale of Operation

    8.3.4.    Analysis by Type of Drug Molecule

    8.3.5.    Analysis by Type of Continuous Manufacturing Related Service

    8.3.6.    Analysis by Type of Dosage Form

    8.3.7.    Most Active Players: Analysis by Number of Partnerships

     

    8.3.8.    Regional Analysis

    8.3.8.1. Intercontinental and Intracontinental Agreements

     

    1. RECENT EXPANSIONS

    9.1.       Chapter Overview

    9.2.       Recent Expansions

    9.2.1.    Analysis by Year of Expansion

    9.2.2.    Analysis by Type of Expansion

    9.2.3.    Analysis by Expanded Scale of Expansion

    9.2.4.    Analysis by Type of Drug Molecule

    9.2.5.    Analysis by Type of Continuous Manufacturing Related Service

    9.2.6.    Analysis by Type of Dosage Form

    9.2.7.    Most Active Players: Analysis by Number of Expansions

     

    9.2.8.    Regional Analysis

    9.2.8.1. Analysis by Location of Expansion Project

     

    1. CAPACITY ANALYSIS

    10.1.     Chapter Overview

    10.2.     Assumptions and Methodology

    10.3.     Global, Continuous Manufacturing Capacity for Small Molecule APIs

    10.3.1.  Analysis by Company Size

    10.3.2. Analysis by Purpose of Manufacturing

    10.3.3.  Analysis by Scale of Operation

    10.3.4.  Analysis by Location of Headquarters

    10.3.4.  Analysis by Location of Continuous Manufacturing Facilities

     

    10.4.     Global, Continuous Manufacturing Capacity for Small Molecule End Products

    10.4.1.  Analysis by Company Size

    10.4.2. Analysis by Purpose of Manufacturing

    10.4.3.  Analysis by Scale of Operation

    10.4.4.  Analysis by Location of Headquarters

    10.4.5.  Analysis by Location of Continuous Manufacturing Facilities

     

    10.5.     Global, Continuous Manufacturing Capacity for Biologic

    10.5.1.  Analysis by Company Size

    10.5.2. Analysis by Purpose of Manufacturing

    10.5.3.  Analysis by Scale of Operation

    10.5.4.  Analysis by Location of Headquarters

    10.5.5.  Analysis by Location of Continuous Manufacturing Facilities

     

    1. ACADEMIC GRANT ANALYSIS

    11.1.     Chapter Overview

    11.2.     Scope and Methodology

    11.3.     Continuous Manufacturing: List of Academic Grants

    11.3.1.  Analysis by Number of Grants

    11.3.2.  Analysis by Activity Code

    11.3.3.  Analysis by Grant Amount

    11.3.4.  Analysis by Focus Area

    11.3.5.  Analysis by Support Period

    11.3.6   Popular Recipient Organizations: Analysis by Number of Grants

    11.3.7   Analysis by Type of Recipient Organization

    11.3.8.  Analysis by Funding Institute Centre

    11.3.9.  Analysis by Funding Mechanism

    11.3.10. Prominent Program Officers: Analysis by Number of Grants

     

    1. PATENT ANALYSIS

    12.1.     Chapter Overview

    12.2.     Scope and Methodology

    12.3.     Continuous Manufacturing: Patent Analysis

    12.3.1.  Analysis by Publication Year

    12.3.2.  Analysis by Geography

    12.3.3.  Analysis by CPC Symbols

    12.3.4.  Emerging Focus Areas

    12.3.5.  Analysis by Type of Applicant

    12.3.6.  Leading Players: Analysis by Number of Patents

    12.3.7.  Continuous Manufacturing: Three-Dimensional Bubble Analysis

    12.3.8.  Continuous Manufacturing: Patent Valuation Analysis

    12.3.8.1. Leading Patents: Information by Number of Citations

     

    1. INITIATIVES OF COMPANIES WITH IN-HOUSE CONTINUOUS MANUFACTURING CAPABILITIES

    13.1.     Chapter Overview

    13.2.     Continuous Manufacturing Initiatives of Leading Companies

    13.2.1.  AbbVie

    13.2.1.1. Partnered Initiatives

    13.2.1.2 In-House Initiatives

     

    13.2.2.  Amgen

    13.2.2.1. Partnered Initiatives

    13.2.2.2. In-House Initiatives

     

    13.2.3.  Bristol-Myers Squibb

    13.2.3.1. Partnered Initiatives

    13.2.3.2. In-House Initiatives

     

    13.2.4.  GlaxoSmithKline

    13.2.4.1. Partnered Initiatives

    13.2.4.2. In-House Initiatives

     

    13.2.5.  Merck

    13.2.5.1. Partnered Initiatives

    13.2.5.2. In-House Initiatives

     

    13.2.6.  Novartis

    13.2.6.1. Partnered Initiatives

    13.2.6.2. In-House Initiatives

     

    13.2.7.  Pfizer

    13.2.7.1. Partnered Initiatives

    13.2.7.2. In-House Initiatives

     

    13.2.8.  Roche

    13.2.8.1. Partnered Initiatives

    13.2.8.2. In-House Initiatives

    13.2.9.  Sanofi

    13.2.9.1. Partnered Initiatives

    13.2.9.2. In-House Initiatives

     

    1. CASE STUDY: MODULAR FACILITIES IN PHARMACEUTICAL / BIOTECHNOLOGY INDUSTRY

    14.1.     Chapter Overview

    14.2.     Historical Background

    14.3.     Concept of Modularization

    14.3.1.  Types of Modules

    14.3.2.  Modular Construction Process

     

    14.4.     Modular Construction in the Pharmaceutical Industry

    14.4.1.  Advantages of Modular Construction in the Pharmaceutical Industry

     

    14.5.     Modular Facility Manufacturers

    14.5.1.  Distribution by Industry Served

    14.5.2.  Distribution by Geography

    14.5.3.  Modular Projects Executed / Undertaken

     

    14.6.     Modular Pharmaceutical Cleanrooms

    14.6.1.  Cleanroom Classification and Current Standards

    14.6.2.  Advantages of Modular Cleanrooms

    14.6.3.  Regulations and Standards Concerning Modular Cleanroom Construction

     

    14.7.     Modular Cleanroom Providers

    14.7.1.  Distribution by Industry Served

    14.7.2.  Distribution by Geography

    14.7.3.  Type of Modular Cleanrooms Offered

     

    1. CASE STUDY: TECHNOLOGY AND EQUIPMENT PROVIDERS

    15.1.     Chapter Overview

    15.2.     Types of Continuous Manufacturing Technologies

    15.3.     Equipment and Technologies for Continuous Manufacturing Small Molecules and Biologics

    15.3.1.  Continuous Blending and Mixing Equipment

    15.3.2.  Continuous Granulating Equipment

    15.3.3.  Continuous Drying Equipment

    15.3.4.  Continuous Compression Equipment

    15.3.5.  Continuous Coating Equipment

    15.3.6.  Continuous Filtration, Continuous Distillation and Continuous Centrifugation Equipment

    15.3.7.  Continuous Chromatography Equipment

    15.3.8.  Continuous Reactors / Bioreactors

    15.3.9.  Full Line Continuous Platforms

    15.3.10. Process Analytical Technologies

    15.3.11. Other Technologies

    15.4.     Logo Landscape: Analysis of Technology Providers by Number and Type of Equipment

     

    1. CASE STUDY: ROADMAP FOR THE ADOPTION OF CONTINUOUS MANUFACTURING PROCESSES

    16.1.     Chapter Overview

    16.2.     Key Strategies for the Adoption of Continuous Manufacturing Processes

    16.2. 1. Phase I: Process Development and Implementation

    16.2. 2. Phase II: Equipment / Technology Development and Installation

    16.2. 3. Phase III: Facility / Plant Development and Establishment

    16.2. 4. Phase IV: Product Development and Manufacturing

     

    1. MARKET FORECAST AND OPPORTUNITY ANALYSIS

    17.1.     Chapter Overview

    17.2.     Forecast Methodology and Key Assumptions

    17.3.     Overall, Continuous Manufacturing Market, 2020-2030

    17.3.1.  Continuous Manufacturing Market: Distribution by Purpose of Manufacturing, 2020-2030

    17.3.2.  Continuous Manufacturing Market: Distribution by Scale of Operation, 2020-2030

    17.3.3.  Continuous Manufacturing Market: Distribution by Type of Drug Molecule, 2020-2030

    17.3.4.  Continuous Manufacturing Market: Distribution by Type of Continuous Manufacturing Related Service, 2020-2030

    17.3.5.  Continuous Manufacturing Market: Distribution by Type of Dosage Form, 2020-2030

    17.3.6.  Continuous Manufacturing Market: Distribution by Key Geographical Regions, 2020-2030

     

    17.4.     Continuous Manufacturing Market for Small Molecule, 2020-2030

    17.4.1.  Distribution by Purpose of Manufacturing, 2020-2030

    17.4.2.  Distribution by Scale of Operation, 2020-2030

    17.4.3.  Distribution by Type of Continuous Manufacturing Related Service, 2020-2030

    17.4.4.  Distribution by Key Geographical Regions, 2020-2030

     

    17.5.     Continuous Manufacturing Market for Biologic, 2020-2030

    17.5.1.  Distribution by Purpose of Manufacturing, 2020-2030

    17.5.2.  Distribution by Scale of Operation, 2020-2030

    17.5.3.  Distribution by Type of Continuous Manufacturing Related Service, 2020-2030

    17.5.4.  Distribution by Key Geographical Regions, 2020-2030

     

    1. CONCLUSION

    18.1.     Chapter Overview

    18.2.     Key Takeaways

     

    1. EXECUTIVE INSIGHTS

    19.1.     Chapter Overview

    19.2.     Zaiput Flow Technologies

    19.2.1.  Company Snapshot

    19.2.2.  Interview Transcript: Andrea Adamo, Founder and Chief Executive Officer

     

    19.3.     CONTINUUS Pharmaceuticals

    19.3.1.  Company Snapshot

    19.3.2.  Interview Transcript: Bayan Takizawa, Co-Founder and Chief Business Officer

     

    19.4.     Snapdragon Chemistry

    19.4.1.  Company Snapshot

    19.4.2.  Interview Transcript: Eric Fang, Chief Scientific Officer

     

    19.5.     Enzene Biosciences

    19.5.1.  Company Snapshot

    19.5.2.  Interview Transcript: Himanshu Gadgil, Director and Chief Scientific Officer

     

    19.6.     Pfizer

    19.6.1.  Company Snapshot

    19.6.2.  Interview Transcript: Nick Thomson, Senior Director Chemical Research and Development

    19.7.     University of Strathclyde

    19.7.1.  Company Snapshot

    19.7.2.  Interview Transcript: Ian Houson, Technical Project Manager

     

     

    1. APPENDIX 1: TABULATED DATA

     

    1. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

     

    Contact Details

    Gaurav Chaudhary

    +1 (415) 800 3415

    gaurav.chaudhary@rootsanalysis.com


  • The continuous manufacturing market is projected to grow at an annualized rate of over 15%

    Roots Analysis has done a detailed study on Continuous Manufacturing Market (Small Molecules and Biologics), 2020 – 2030, covering key aspects of the industry and identifying future growth opportunities.

     

    To order this 310+ page report, which features 110+ figures and 200+ tables, please visit this link

     

    Key Market Insights

    • Eminent representatives from prominent contract service provider companies / organizations are both optimistic and cautious regarding the rising interest in continuous flow technologies, and its adoption
    • Over 60 companies across the globe claim to manufacture drug products / drug substances using the continuous manufacturing technique, either for in-house requirements or for contract service engagements
    • The market landscape features the presence of several well-established players, most of which claim to manufacture small molecules via the continuous technique, and are based in the developed geographies
    • Companies have established continuous drug manufacturing facilities for diverse types of dosage forms in various geographies; Europe and North America have emerged as the key hubs for these facilities
    • Several patents have been filed / granted specifically related to continuous manufacturing of pharmaceutical substances, both industry and non-industry players are actively involved in such efforts
    • Organizations have also extended financial support to aid the research efforts being put by various stakeholders in this domain; the current focus is on investigation of continuous manufacturing technologies
    • Over time, there has been a lot of activity in this arena, including the establishment of several partnerships and investments in capability and capacity expansions and new facilities worldwide
    • Most of the continuous manufacturing capacity belongs to established companies (in-house manufacturers and CMOs), accounting for over 70% of the available capacity across various geographies
    • Involvement of various other stakeholders including continuous equipment providers and modular facility providers is likely to revolutionize the overall manufacturing domain
    • As the adoption of continuous manufacturing technologies increases, the market is likely to witness significant growth; in the short term, majority of service-based revenues is likely to come from drug product related projects

     

    For more information, please visit https://www.rootsanalysis.com/reports/view_document/continuous-manufacturing/308.html

     

    Table of Contents

     

    TABLE OF CONTENTS

     

    1. PREFACE

    1.1.       Scope of the Report

    1.2.       Research Methodology

    1.3.       Chapter Outlines

     

    1. EXECUTIVE SUMMARY

     

    1. INTRODUCTION

    3.1.       Chapter Overview

    3.2.       Historical Evolution of Continuous Manufacturing

    3.3.       Continuous Manufacturing in the Pharmaceutical Industry

    3.3.1.    Regulatory Landscape

    3.3.2.    Early Adopters of Continuous Manufacturing

    3.3.3.    Anticipated Shift to Continuous Manufacturing

    3.3.4.    Advantages of Continuous Manufacturing

    3.3.5.    Key Challenges Associated with Continuous Manufacturing

    3.3.6.    Future Perspectives

     

    1. MARKET LANDSCAPE

    4.1.       Chapter Overview

    4.2.       Companies with Expertise in Continuous Manufacturing: Overall Market Landscape

    4.2.1.    Analysis by Year of Establishment

    4.2.2.    Analysis by Company Size

    4.2.3.    Analysis by Purpose of Manufacturing

    4.2.4.    Analysis by Scale of Operation

    4.2.5.    Analysis by Location of Headquarters

    4.2.6.    Analysis by Location of Continuous Manufacturing Facilities

    4.2.7.    Analysis by Type of Drug Molecule

    4.2.8.    Analysis by Type of Continuous Manufacturing Related Service

    4.2.9.    Analysis by Type of Dosage Form

    4.2.10.  Heat Map: Analysis by Company Size and Location of Headquarters

    4.2.11.  Information on Production Capacity

    4.2.12.  Logo Landscape: Analysis by Year of Establishment and Company Size 

    4.2.13.  Grid Representation: Analysis by Scale of Operation, Type of Continuous Manufacturing Related Service and Type of Dosage Form

    4.2.14.  Geographical Map: Analysis by Location of Continuous Manufacturing Facilities and Type of Drug Molecule

     

    1. COMPANIES WITH EXPERTISE IN CONTINUOUS MANUFACTURING IN NORTH AMERICA: PROFILES

    5.1.       Chapter Overview

    5.2.       AbbVie Contract Manufacturing

    5.2.1.    Company Overview

    5.2.2.    Service Portfolio

    5.2.3.    Continuous Manufacturing Capabilities and Facilities

    5.2.4.    Recent Developments and Future Outlook

     

    5.3.       Cambrex

    5.3.1.    Company Overview

    5.3.2.    Service Portfolio

    5.3.3.    Continuous Manufacturing Capabilities and Facilities

    5.3.4.    Recent Developments and Future Outlook

     

    5.4.       Patheon

    5.4.1.    Company Overview

    5.4.2.    Service Portfolio

    5.4.3.    Continuous Manufacturing Capabilities and Facilities

    5.4.4.    Recent Developments and Future Outlook

     

    5.5.       SK biotek

    5.5.1.    Company Overview

    5.5.2.    Service Portfolio

    5.5.3.    Continuous Manufacturing Capabilities and Facilities

    5.5.4.    Recent Developments and Future Outlook

     

    1. COMPANIES WITH EXPERTISE IN CONTINUOUS MANUFACTURING IN EUROPE: PROFILES

    6.1.       Chapter Overview

    6.2.       Ajinomoto Bio-Pharma Services

    6.2.1.    Company Overview

    6.2.2.    Service Portfolio

    6.2.3.    Continuous Manufacturing Capabilities and Facilities

    6.2.4.    Recent Developments and Future Outlook

     

    6.3.       Almac

    6.3.1.    Company Overview

    6.3.2.    Service Portfolio

    6.3.3.    Continuous Manufacturing Capabilities and Facilities

    6.3.4.    Recent Developments and Future Outlook

     

    6.4.       Boehringer Ingelheim BioXcellence™

    6.4.1.    Company Overview

    6.4.2.    Service Portfolio

    6.4.3.    Continuous Manufacturing Capabilities and Facilities

    6.4.4.    Recent Developments and Future Outlook

     

    6.5.       CordonPharma

    6.5.1.    Company Overview

    6.5.2.    Service Portfolio

    6.5.3.    Continuous Manufacturing Capabilities and Facilities

    6.5.4.    Recent Developments and Future Outlook

     

    6.6.       Hovione

    6.6.1.    Company Overview

    6.6.2.    Service Portfolio

    6.6.3.    Continuous Manufacturing Capabilities and Facilities

    6.6.4.    Recent Developments and Future Outlook

     

    6.7.       Lonza

    6.7.1.    Company Overview

    6.7.2.    Service Portfolio

    6.7.3.    Continuous Manufacturing Capabilities and Facilities

    6.7.4.    Recent Developments and Future Outlook

     

    1. COMPANIES WITH EXPERTISE IN CONTINUOUS MANUFACTURING IN ASIA-PACIFIC: PROFILES

    7.1.       Chapter Overview

    7.2.       Kaneka

    7.2.1.    Company Overview

    7.2.2.    Service Portfolio

    7.2.3.    Continuous Manufacturing Capabilities and Facilities

    7.2.4.    Recent Developments and Future Outlook     

     

    7.3.       WuXi AppTec

    7.3.1.    Company Overview

    7.3.2.    Service Portfolio

    7.3.3.    Continuous Manufacturing Capabilities and Facilities

    7.3.4.    Recent Developments and Future Outlook                 

     

    1. RECENT PARTNERSHIPS AND COLLABORATIONS

    8.1.       Chapter Overview

    8.2.       Partnership Models

    8.3.       List of Partnerships and Collaborations

    8.3.1.    Analysis by Year of Partnership

    8.3.2.    Analysis by Type of Partnership

    8.3.3.    Analysis by Scale of Operation

    8.3.4.    Analysis by Type of Drug Molecule

    8.3.5.    Analysis by Type of Continuous Manufacturing Related Service

    8.3.6.    Analysis by Type of Dosage Form

    8.3.7.    Most Active Players: Analysis by Number of Partnerships

     

    8.3.8.    Regional Analysis

    8.3.8.1. Intercontinental and Intracontinental Agreements

     

    1. RECENT EXPANSIONS

    9.1.       Chapter Overview

    9.2.       Recent Expansions

    9.2.1.    Analysis by Year of Expansion

    9.2.2.    Analysis by Type of Expansion

    9.2.3.    Analysis by Expanded Scale of Expansion

    9.2.4.    Analysis by Type of Drug Molecule

    9.2.5.    Analysis by Type of Continuous Manufacturing Related Service

    9.2.6.    Analysis by Type of Dosage Form

    9.2.7.    Most Active Players: Analysis by Number of Expansions

     

    9.2.8.    Regional Analysis

    9.2.8.1. Analysis by Location of Expansion Project

     

    1. CAPACITY ANALYSIS

    10.1.     Chapter Overview

    10.2.     Assumptions and Methodology

    10.3.     Global, Continuous Manufacturing Capacity for Small Molecule APIs

    10.3.1.  Analysis by Company Size

    10.3.2. Analysis by Purpose of Manufacturing

    10.3.3.  Analysis by Scale of Operation

    10.3.4.  Analysis by Location of Headquarters

    10.3.4.  Analysis by Location of Continuous Manufacturing Facilities

     

    10.4.     Global, Continuous Manufacturing Capacity for Small Molecule End Products

    10.4.1.  Analysis by Company Size

    10.4.2. Analysis by Purpose of Manufacturing

    10.4.3.  Analysis by Scale of Operation

    10.4.4.  Analysis by Location of Headquarters

    10.4.5.  Analysis by Location of Continuous Manufacturing Facilities

     

    10.5.     Global, Continuous Manufacturing Capacity for Biologic

    10.5.1.  Analysis by Company Size

    10.5.2. Analysis by Purpose of Manufacturing

    10.5.3.  Analysis by Scale of Operation

    10.5.4.  Analysis by Location of Headquarters

    10.5.5.  Analysis by Location of Continuous Manufacturing Facilities

     

    1. ACADEMIC GRANT ANALYSIS

    11.1.     Chapter Overview

    11.2.     Scope and Methodology

    11.3.     Continuous Manufacturing: List of Academic Grants

    11.3.1.  Analysis by Number of Grants

    11.3.2.  Analysis by Activity Code

    11.3.3.  Analysis by Grant Amount

    11.3.4.  Analysis by Focus Area

    11.3.5.  Analysis by Support Period

    11.3.6   Popular Recipient Organizations: Analysis by Number of Grants

    11.3.7   Analysis by Type of Recipient Organization

    11.3.8.  Analysis by Funding Institute Centre

    11.3.9.  Analysis by Funding Mechanism

    11.3.10. Prominent Program Officers: Analysis by Number of Grants

     

    1. PATENT ANALYSIS

    12.1.     Chapter Overview

    12.2.     Scope and Methodology

    12.3.     Continuous Manufacturing: Patent Analysis

    12.3.1.  Analysis by Publication Year

    12.3.2.  Analysis by Geography

    12.3.3.  Analysis by CPC Symbols

    12.3.4.  Emerging Focus Areas

    12.3.5.  Analysis by Type of Applicant

    12.3.6.  Leading Players: Analysis by Number of Patents

    12.3.7.  Continuous Manufacturing: Three-Dimensional Bubble Analysis

    12.3.8.  Continuous Manufacturing: Patent Valuation Analysis

    12.3.8.1. Leading Patents: Information by Number of Citations

     

    1. INITIATIVES OF COMPANIES WITH IN-HOUSE CONTINUOUS MANUFACTURING CAPABILITIES

    13.1.     Chapter Overview

    13.2.     Continuous Manufacturing Initiatives of Leading Companies

    13.2.1.  AbbVie

    13.2.1.1. Partnered Initiatives

    13.2.1.2 In-House Initiatives

     

    13.2.2.  Amgen

    13.2.2.1. Partnered Initiatives

    13.2.2.2. In-House Initiatives

     

    13.2.3.  Bristol-Myers Squibb

    13.2.3.1. Partnered Initiatives

    13.2.3.2. In-House Initiatives

     

    13.2.4.  GlaxoSmithKline

    13.2.4.1. Partnered Initiatives

    13.2.4.2. In-House Initiatives

     

    13.2.5.  Merck

    13.2.5.1. Partnered Initiatives

    13.2.5.2. In-House Initiatives

     

    13.2.6.  Novartis

    13.2.6.1. Partnered Initiatives

    13.2.6.2. In-House Initiatives

     

    13.2.7.  Pfizer

    13.2.7.1. Partnered Initiatives

    13.2.7.2. In-House Initiatives

     

    13.2.8.  Roche

    13.2.8.1. Partnered Initiatives

    13.2.8.2. In-House Initiatives

    13.2.9.  Sanofi

    13.2.9.1. Partnered Initiatives

    13.2.9.2. In-House Initiatives

     

    1. CASE STUDY: MODULAR FACILITIES IN PHARMACEUTICAL / BIOTECHNOLOGY INDUSTRY

    14.1.     Chapter Overview

    14.2.     Historical Background

    14.3.     Concept of Modularization

    14.3.1.  Types of Modules

    14.3.2.  Modular Construction Process

     

    14.4.     Modular Construction in the Pharmaceutical Industry

    14.4.1.  Advantages of Modular Construction in the Pharmaceutical Industry

     

    14.5.     Modular Facility Manufacturers

    14.5.1.  Distribution by Industry Served

    14.5.2.  Distribution by Geography

    14.5.3.  Modular Projects Executed / Undertaken

     

    14.6.     Modular Pharmaceutical Cleanrooms

    14.6.1.  Cleanroom Classification and Current Standards

    14.6.2.  Advantages of Modular Cleanrooms

    14.6.3.  Regulations and Standards Concerning Modular Cleanroom Construction

     

    14.7.     Modular Cleanroom Providers

    14.7.1.  Distribution by Industry Served

    14.7.2.  Distribution by Geography

    14.7.3.  Type of Modular Cleanrooms Offered

     

    1. CASE STUDY: TECHNOLOGY AND EQUIPMENT PROVIDERS

    15.1.     Chapter Overview

    15.2.     Types of Continuous Manufacturing Technologies

    15.3.     Equipment and Technologies for Continuous Manufacturing Small Molecules and Biologics

    15.3.1.  Continuous Blending and Mixing Equipment

    15.3.2.  Continuous Granulating Equipment

    15.3.3.  Continuous Drying Equipment

    15.3.4.  Continuous Compression Equipment

    15.3.5.  Continuous Coating Equipment

    15.3.6.  Continuous Filtration, Continuous Distillation and Continuous Centrifugation Equipment

    15.3.7.  Continuous Chromatography Equipment

    15.3.8.  Continuous Reactors / Bioreactors

    15.3.9.  Full Line Continuous Platforms

    15.3.10. Process Analytical Technologies

    15.3.11. Other Technologies

    15.4.     Logo Landscape: Analysis of Technology Providers by Number and Type of Equipment

     

    1. CASE STUDY: ROADMAP FOR THE ADOPTION OF CONTINUOUS MANUFACTURING PROCESSES

    16.1.     Chapter Overview

    16.2.     Key Strategies for the Adoption of Continuous Manufacturing Processes

    16.2. 1. Phase I: Process Development and Implementation

    16.2. 2. Phase II: Equipment / Technology Development and Installation

    16.2. 3. Phase III: Facility / Plant Development and Establishment

    16.2. 4. Phase IV: Product Development and Manufacturing

     

    1. MARKET FORECAST AND OPPORTUNITY ANALYSIS

    17.1.     Chapter Overview

    17.2.     Forecast Methodology and Key Assumptions

    17.3.     Overall, Continuous Manufacturing Market, 2020-2030

    17.3.1.  Continuous Manufacturing Market: Distribution by Purpose of Manufacturing, 2020-2030

    17.3.2.  Continuous Manufacturing Market: Distribution by Scale of Operation, 2020-2030

    17.3.3.  Continuous Manufacturing Market: Distribution by Type of Drug Molecule, 2020-2030

    17.3.4.  Continuous Manufacturing Market: Distribution by Type of Continuous Manufacturing Related Service, 2020-2030

    17.3.5.  Continuous Manufacturing Market: Distribution by Type of Dosage Form, 2020-2030

    17.3.6.  Continuous Manufacturing Market: Distribution by Key Geographical Regions, 2020-2030

     

    17.4.     Continuous Manufacturing Market for Small Molecule, 2020-2030

    17.4.1.  Distribution by Purpose of Manufacturing, 2020-2030

    17.4.2.  Distribution by Scale of Operation, 2020-2030

    17.4.3.  Distribution by Type of Continuous Manufacturing Related Service, 2020-2030

    17.4.4.  Distribution by Key Geographical Regions, 2020-2030

     

    17.5.     Continuous Manufacturing Market for Biologic, 2020-2030

    17.5.1.  Distribution by Purpose of Manufacturing, 2020-2030

    17.5.2.  Distribution by Scale of Operation, 2020-2030

    17.5.3.  Distribution by Type of Continuous Manufacturing Related Service, 2020-2030

    17.5.4.  Distribution by Key Geographical Regions, 2020-2030

     

    1. CONCLUSION

    18.1.     Chapter Overview

    18.2.     Key Takeaways

     

    1. EXECUTIVE INSIGHTS

    19.1.     Chapter Overview

    19.2.     Zaiput Flow Technologies

    19.2.1.  Company Snapshot

    19.2.2.  Interview Transcript: Andrea Adamo, Founder and Chief Executive Officer

     

    19.3.     CONTINUUS Pharmaceuticals

    19.3.1.  Company Snapshot

    19.3.2.  Interview Transcript: Bayan Takizawa, Co-Founder and Chief Business Officer

     

    19.4.     Snapdragon Chemistry

    19.4.1.  Company Snapshot

    19.4.2.  Interview Transcript: Eric Fang, Chief Scientific Officer

     

    19.5.     Enzene Biosciences

    19.5.1.  Company Snapshot

    19.5.2.  Interview Transcript: Himanshu Gadgil, Director and Chief Scientific Officer

     

    19.6.     Pfizer

    19.6.1.  Company Snapshot

    19.6.2.  Interview Transcript: Nick Thomson, Senior Director Chemical Research and Development

    19.7.     University of Strathclyde

    19.7.1.  Company Snapshot

    19.7.2.  Interview Transcript: Ian Houson, Technical Project Manager

     

     

    1. APPENDIX 1: TABULATED DATA

     

    1. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

     

    Contact Details

    Gaurav Chaudhary

    +1 (415) 800 3415

    gaurav.chaudhary@rootsanalysis.com


  • The continuous manufacturing market is projected to grow at an annualized rate of over 15%

    Roots Analysis has done a detailed study on Continuous Manufacturing Market (Small Molecules and Biologics), 2020 – 2030, covering key aspects of the industry and identifying future growth opportunities.

     

    To order this 310+ page report, which features 110+ figures and 200+ tables, please visit this link

     

    Key Market Insights

    • Eminent representatives from prominent contract service provider companies / organizations are both optimistic and cautious regarding the rising interest in continuous flow technologies, and its adoption
    • Over 60 companies across the globe claim to manufacture drug products / drug substances using the continuous manufacturing technique, either for in-house requirements or for contract service engagements
    • The market landscape features the presence of several well-established players, most of which claim to manufacture small molecules via the continuous technique, and are based in the developed geographies
    • Companies have established continuous drug manufacturing facilities for diverse types of dosage forms in various geographies; Europe and North America have emerged as the key hubs for these facilities
    • Several patents have been filed / granted specifically related to continuous manufacturing of pharmaceutical substances, both industry and non-industry players are actively involved in such efforts
    • Organizations have also extended financial support to aid the research efforts being put by various stakeholders in this domain; the current focus is on investigation of continuous manufacturing technologies
    • Over time, there has been a lot of activity in this arena, including the establishment of several partnerships and investments in capability and capacity expansions and new facilities worldwide
    • Most of the continuous manufacturing capacity belongs to established companies (in-house manufacturers and CMOs), accounting for over 70% of the available capacity across various geographies
    • Involvement of various other stakeholders including continuous equipment providers and modular facility providers is likely to revolutionize the overall manufacturing domain
    • As the adoption of continuous manufacturing technologies increases, the market is likely to witness significant growth; in the short term, majority of service-based revenues is likely to come from drug product related projects

     

    For more information, please visit https://www.rootsanalysis.com/reports/view_document/continuous-manufacturing/308.html

     

    Table of Contents

     

    TABLE OF CONTENTS

     

    1. PREFACE

    1.1.       Scope of the Report

    1.2.       Research Methodology

    1.3.       Chapter Outlines

     

    1. EXECUTIVE SUMMARY

     

    1. INTRODUCTION

    3.1.       Chapter Overview

    3.2.       Historical Evolution of Continuous Manufacturing

    3.3.       Continuous Manufacturing in the Pharmaceutical Industry

    3.3.1.    Regulatory Landscape

    3.3.2.    Early Adopters of Continuous Manufacturing

    3.3.3.    Anticipated Shift to Continuous Manufacturing

    3.3.4.    Advantages of Continuous Manufacturing

    3.3.5.    Key Challenges Associated with Continuous Manufacturing

    3.3.6.    Future Perspectives

     

    1. MARKET LANDSCAPE

    4.1.       Chapter Overview

    4.2.       Companies with Expertise in Continuous Manufacturing: Overall Market Landscape

    4.2.1.    Analysis by Year of Establishment

    4.2.2.    Analysis by Company Size

    4.2.3.    Analysis by Purpose of Manufacturing

    4.2.4.    Analysis by Scale of Operation

    4.2.5.    Analysis by Location of Headquarters

    4.2.6.    Analysis by Location of Continuous Manufacturing Facilities

    4.2.7.    Analysis by Type of Drug Molecule

    4.2.8.    Analysis by Type of Continuous Manufacturing Related Service

    4.2.9.    Analysis by Type of Dosage Form

    4.2.10.  Heat Map: Analysis by Company Size and Location of Headquarters

    4.2.11.  Information on Production Capacity

    4.2.12.  Logo Landscape: Analysis by Year of Establishment and Company Size 

    4.2.13.  Grid Representation: Analysis by Scale of Operation, Type of Continuous Manufacturing Related Service and Type of Dosage Form

    4.2.14.  Geographical Map: Analysis by Location of Continuous Manufacturing Facilities and Type of Drug Molecule

     

    1. COMPANIES WITH EXPERTISE IN CONTINUOUS MANUFACTURING IN NORTH AMERICA: PROFILES

    5.1.       Chapter Overview

    5.2.       AbbVie Contract Manufacturing

    5.2.1.    Company Overview

    5.2.2.    Service Portfolio

    5.2.3.    Continuous Manufacturing Capabilities and Facilities

    5.2.4.    Recent Developments and Future Outlook

     

    5.3.       Cambrex

    5.3.1.    Company Overview

    5.3.2.    Service Portfolio

    5.3.3.    Continuous Manufacturing Capabilities and Facilities

    5.3.4.    Recent Developments and Future Outlook

     

    5.4.       Patheon

    5.4.1.    Company Overview

    5.4.2.    Service Portfolio

    5.4.3.    Continuous Manufacturing Capabilities and Facilities

    5.4.4.    Recent Developments and Future Outlook

     

    5.5.       SK biotek

    5.5.1.    Company Overview

    5.5.2.    Service Portfolio

    5.5.3.    Continuous Manufacturing Capabilities and Facilities

    5.5.4.    Recent Developments and Future Outlook

     

    1. COMPANIES WITH EXPERTISE IN CONTINUOUS MANUFACTURING IN EUROPE: PROFILES

    6.1.       Chapter Overview

    6.2.       Ajinomoto Bio-Pharma Services

    6.2.1.    Company Overview

    6.2.2.    Service Portfolio

    6.2.3.    Continuous Manufacturing Capabilities and Facilities

    6.2.4.    Recent Developments and Future Outlook

     

    6.3.       Almac

    6.3.1.    Company Overview

    6.3.2.    Service Portfolio

    6.3.3.    Continuous Manufacturing Capabilities and Facilities

    6.3.4.    Recent Developments and Future Outlook

     

    6.4.       Boehringer Ingelheim BioXcellence™

    6.4.1.    Company Overview

    6.4.2.    Service Portfolio

    6.4.3.    Continuous Manufacturing Capabilities and Facilities

    6.4.4.    Recent Developments and Future Outlook

     

    6.5.       CordonPharma

    6.5.1.    Company Overview

    6.5.2.    Service Portfolio

    6.5.3.    Continuous Manufacturing Capabilities and Facilities

    6.5.4.    Recent Developments and Future Outlook

     

    6.6.       Hovione

    6.6.1.    Company Overview

    6.6.2.    Service Portfolio

    6.6.3.    Continuous Manufacturing Capabilities and Facilities

    6.6.4.    Recent Developments and Future Outlook

     

    6.7.       Lonza

    6.7.1.    Company Overview

    6.7.2.    Service Portfolio

    6.7.3.    Continuous Manufacturing Capabilities and Facilities

    6.7.4.    Recent Developments and Future Outlook

     

    1. COMPANIES WITH EXPERTISE IN CONTINUOUS MANUFACTURING IN ASIA-PACIFIC: PROFILES

    7.1.       Chapter Overview

    7.2.       Kaneka

    7.2.1.    Company Overview

    7.2.2.    Service Portfolio

    7.2.3.    Continuous Manufacturing Capabilities and Facilities

    7.2.4.    Recent Developments and Future Outlook     

     

    7.3.       WuXi AppTec

    7.3.1.    Company Overview

    7.3.2.    Service Portfolio

    7.3.3.    Continuous Manufacturing Capabilities and Facilities

    7.3.4.    Recent Developments and Future Outlook                 

     

    1. RECENT PARTNERSHIPS AND COLLABORATIONS

    8.1.       Chapter Overview

    8.2.       Partnership Models

    8.3.       List of Partnerships and Collaborations

    8.3.1.    Analysis by Year of Partnership

    8.3.2.    Analysis by Type of Partnership

    8.3.3.    Analysis by Scale of Operation

    8.3.4.    Analysis by Type of Drug Molecule

    8.3.5.    Analysis by Type of Continuous Manufacturing Related Service

    8.3.6.    Analysis by Type of Dosage Form

    8.3.7.    Most Active Players: Analysis by Number of Partnerships

     

    8.3.8.    Regional Analysis

    8.3.8.1. Intercontinental and Intracontinental Agreements

     

    1. RECENT EXPANSIONS

    9.1.       Chapter Overview

    9.2.       Recent Expansions

    9.2.1.    Analysis by Year of Expansion

    9.2.2.    Analysis by Type of Expansion

    9.2.3.    Analysis by Expanded Scale of Expansion

    9.2.4.    Analysis by Type of Drug Molecule

    9.2.5.    Analysis by Type of Continuous Manufacturing Related Service

    9.2.6.    Analysis by Type of Dosage Form

    9.2.7.    Most Active Players: Analysis by Number of Expansions

     

    9.2.8.    Regional Analysis

    9.2.8.1. Analysis by Location of Expansion Project

     

    1. CAPACITY ANALYSIS

    10.1.     Chapter Overview

    10.2.     Assumptions and Methodology

    10.3.     Global, Continuous Manufacturing Capacity for Small Molecule APIs

    10.3.1.  Analysis by Company Size

    10.3.2. Analysis by Purpose of Manufacturing

    10.3.3.  Analysis by Scale of Operation

    10.3.4.  Analysis by Location of Headquarters

    10.3.4.  Analysis by Location of Continuous Manufacturing Facilities

     

    10.4.     Global, Continuous Manufacturing Capacity for Small Molecule End Products

    10.4.1.  Analysis by Company Size

    10.4.2. Analysis by Purpose of Manufacturing

    10.4.3.  Analysis by Scale of Operation

    10.4.4.  Analysis by Location of Headquarters

    10.4.5.  Analysis by Location of Continuous Manufacturing Facilities

     

    10.5.     Global, Continuous Manufacturing Capacity for Biologic

    10.5.1.  Analysis by Company Size

    10.5.2. Analysis by Purpose of Manufacturing

    10.5.3.  Analysis by Scale of Operation

    10.5.4.  Analysis by Location of Headquarters

    10.5.5.  Analysis by Location of Continuous Manufacturing Facilities

     

    1. ACADEMIC GRANT ANALYSIS

    11.1.     Chapter Overview

    11.2.     Scope and Methodology

    11.3.     Continuous Manufacturing: List of Academic Grants

    11.3.1.  Analysis by Number of Grants

    11.3.2.  Analysis by Activity Code

    11.3.3.  Analysis by Grant Amount

    11.3.4.  Analysis by Focus Area

    11.3.5.  Analysis by Support Period

    11.3.6   Popular Recipient Organizations: Analysis by Number of Grants

    11.3.7   Analysis by Type of Recipient Organization

    11.3.8.  Analysis by Funding Institute Centre

    11.3.9.  Analysis by Funding Mechanism

    11.3.10. Prominent Program Officers: Analysis by Number of Grants

     

    1. PATENT ANALYSIS

    12.1.     Chapter Overview

    12.2.     Scope and Methodology

    12.3.     Continuous Manufacturing: Patent Analysis

    12.3.1.  Analysis by Publication Year

    12.3.2.  Analysis by Geography

    12.3.3.  Analysis by CPC Symbols

    12.3.4.  Emerging Focus Areas

    12.3.5.  Analysis by Type of Applicant

    12.3.6.  Leading Players: Analysis by Number of Patents

    12.3.7.  Continuous Manufacturing: Three-Dimensional Bubble Analysis

    12.3.8.  Continuous Manufacturing: Patent Valuation Analysis

    12.3.8.1. Leading Patents: Information by Number of Citations

     

    1. INITIATIVES OF COMPANIES WITH IN-HOUSE CONTINUOUS MANUFACTURING CAPABILITIES

    13.1.     Chapter Overview

    13.2.     Continuous Manufacturing Initiatives of Leading Companies

    13.2.1.  AbbVie

    13.2.1.1. Partnered Initiatives

    13.2.1.2 In-House Initiatives

     

    13.2.2.  Amgen

    13.2.2.1. Partnered Initiatives

    13.2.2.2. In-House Initiatives

     

    13.2.3.  Bristol-Myers Squibb

    13.2.3.1. Partnered Initiatives

    13.2.3.2. In-House Initiatives

     

    13.2.4.  GlaxoSmithKline

    13.2.4.1. Partnered Initiatives

    13.2.4.2. In-House Initiatives

     

    13.2.5.  Merck

    13.2.5.1. Partnered Initiatives

    13.2.5.2. In-House Initiatives

     

    13.2.6.  Novartis

    13.2.6.1. Partnered Initiatives

    13.2.6.2. In-House Initiatives

     

    13.2.7.  Pfizer

    13.2.7.1. Partnered Initiatives

    13.2.7.2. In-House Initiatives

     

    13.2.8.  Roche

    13.2.8.1. Partnered Initiatives

    13.2.8.2. In-House Initiatives

    13.2.9.  Sanofi

    13.2.9.1. Partnered Initiatives

    13.2.9.2. In-House Initiatives

     

    1. CASE STUDY: MODULAR FACILITIES IN PHARMACEUTICAL / BIOTECHNOLOGY INDUSTRY

    14.1.     Chapter Overview

    14.2.     Historical Background

    14.3.     Concept of Modularization

    14.3.1.  Types of Modules

    14.3.2.  Modular Construction Process

     

    14.4.     Modular Construction in the Pharmaceutical Industry

    14.4.1.  Advantages of Modular Construction in the Pharmaceutical Industry

     

    14.5.     Modular Facility Manufacturers

    14.5.1.  Distribution by Industry Served

    14.5.2.  Distribution by Geography

    14.5.3.  Modular Projects Executed / Undertaken

     

    14.6.     Modular Pharmaceutical Cleanrooms

    14.6.1.  Cleanroom Classification and Current Standards

    14.6.2.  Advantages of Modular Cleanrooms

    14.6.3.  Regulations and Standards Concerning Modular Cleanroom Construction

     

    14.7.     Modular Cleanroom Providers

    14.7.1.  Distribution by Industry Served

    14.7.2.  Distribution by Geography

    14.7.3.  Type of Modular Cleanrooms Offered

     

    1. CASE STUDY: TECHNOLOGY AND EQUIPMENT PROVIDERS

    15.1.     Chapter Overview

    15.2.     Types of Continuous Manufacturing Technologies

    15.3.     Equipment and Technologies for Continuous Manufacturing Small Molecules and Biologics

    15.3.1.  Continuous Blending and Mixing Equipment

    15.3.2.  Continuous Granulating Equipment

    15.3.3.  Continuous Drying Equipment

    15.3.4.  Continuous Compression Equipment

    15.3.5.  Continuous Coating Equipment

    15.3.6.  Continuous Filtration, Continuous Distillation and Continuous Centrifugation Equipment

    15.3.7.  Continuous Chromatography Equipment

    15.3.8.  Continuous Reactors / Bioreactors

    15.3.9.  Full Line Continuous Platforms

    15.3.10. Process Analytical Technologies

    15.3.11. Other Technologies

    15.4.     Logo Landscape: Analysis of Technology Providers by Number and Type of Equipment

     

    1. CASE STUDY: ROADMAP FOR THE ADOPTION OF CONTINUOUS MANUFACTURING PROCESSES

    16.1.     Chapter Overview

    16.2.     Key Strategies for the Adoption of Continuous Manufacturing Processes

    16.2. 1. Phase I: Process Development and Implementation

    16.2. 2. Phase II: Equipment / Technology Development and Installation

    16.2. 3. Phase III: Facility / Plant Development and Establishment

    16.2. 4. Phase IV: Product Development and Manufacturing

     

    1. MARKET FORECAST AND OPPORTUNITY ANALYSIS

    17.1.     Chapter Overview

    17.2.     Forecast Methodology and Key Assumptions

    17.3.     Overall, Continuous Manufacturing Market, 2020-2030

    17.3.1.  Continuous Manufacturing Market: Distribution by Purpose of Manufacturing, 2020-2030

    17.3.2.  Continuous Manufacturing Market: Distribution by Scale of Operation, 2020-2030

    17.3.3.  Continuous Manufacturing Market: Distribution by Type of Drug Molecule, 2020-2030

    17.3.4.  Continuous Manufacturing Market: Distribution by Type of Continuous Manufacturing Related Service, 2020-2030

    17.3.5.  Continuous Manufacturing Market: Distribution by Type of Dosage Form, 2020-2030

    17.3.6.  Continuous Manufacturing Market: Distribution by Key Geographical Regions, 2020-2030

     

    17.4.     Continuous Manufacturing Market for Small Molecule, 2020-2030

    17.4.1.  Distribution by Purpose of Manufacturing, 2020-2030

    17.4.2.  Distribution by Scale of Operation, 2020-2030

    17.4.3.  Distribution by Type of Continuous Manufacturing Related Service, 2020-2030

    17.4.4.  Distribution by Key Geographical Regions, 2020-2030

     

    17.5.     Continuous Manufacturing Market for Biologic, 2020-2030

    17.5.1.  Distribution by Purpose of Manufacturing, 2020-2030

    17.5.2.  Distribution by Scale of Operation, 2020-2030

    17.5.3.  Distribution by Type of Continuous Manufacturing Related Service, 2020-2030

    17.5.4.  Distribution by Key Geographical Regions, 2020-2030

     

    1. CONCLUSION

    18.1.     Chapter Overview

    18.2.     Key Takeaways

     

    1. EXECUTIVE INSIGHTS

    19.1.     Chapter Overview

    19.2.     Zaiput Flow Technologies

    19.2.1.  Company Snapshot

    19.2.2.  Interview Transcript: Andrea Adamo, Founder and Chief Executive Officer

     

    19.3.     CONTINUUS Pharmaceuticals

    19.3.1.  Company Snapshot

    19.3.2.  Interview Transcript: Bayan Takizawa, Co-Founder and Chief Business Officer

     

    19.4.     Snapdragon Chemistry

    19.4.1.  Company Snapshot

    19.4.2.  Interview Transcript: Eric Fang, Chief Scientific Officer

     

    19.5.     Enzene Biosciences

    19.5.1.  Company Snapshot

    19.5.2.  Interview Transcript: Himanshu Gadgil, Director and Chief Scientific Officer

     

    19.6.     Pfizer

    19.6.1.  Company Snapshot

    19.6.2.  Interview Transcript: Nick Thomson, Senior Director Chemical Research and Development

    19.7.     University of Strathclyde

    19.7.1.  Company Snapshot

    19.7.2.  Interview Transcript: Ian Houson, Technical Project Manager

     

     

    1. APPENDIX 1: TABULATED DATA

     

    1. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

     

    Contact Details

    Gaurav Chaudhary

    +1 (415) 800 3415

    gaurav.chaudhary@rootsanalysis.com


  • The continuous manufacturing market is projected to grow at an annualized rate of over 15%

    Roots Analysis has done a detailed study on Continuous Manufacturing Market (Small Molecules and Biologics), 2020 – 2030, covering key aspects of the industry and identifying future growth opportunities.

     

    To order this 310+ page report, which features 110+ figures and 200+ tables, please visit this link

     

    Key Market Insights

    • Eminent representatives from prominent contract service provider companies / organizations are both optimistic and cautious regarding the rising interest in continuous flow technologies, and its adoption
    • Over 60 companies across the globe claim to manufacture drug products / drug substances using the continuous manufacturing technique, either for in-house requirements or for contract service engagements
    • The market landscape features the presence of several well-established players, most of which claim to manufacture small molecules via the continuous technique, and are based in the developed geographies
    • Companies have established continuous drug manufacturing facilities for diverse types of dosage forms in various geographies; Europe and North America have emerged as the key hubs for these facilities
    • Several patents have been filed / granted specifically related to continuous manufacturing of pharmaceutical substances, both industry and non-industry players are actively involved in such efforts
    • Organizations have also extended financial support to aid the research efforts being put by various stakeholders in this domain; the current focus is on investigation of continuous manufacturing technologies
    • Over time, there has been a lot of activity in this arena, including the establishment of several partnerships and investments in capability and capacity expansions and new facilities worldwide
    • Most of the continuous manufacturing capacity belongs to established companies (in-house manufacturers and CMOs), accounting for over 70% of the available capacity across various geographies
    • Involvement of various other stakeholders including continuous equipment providers and modular facility providers is likely to revolutionize the overall manufacturing domain
    • As the adoption of continuous manufacturing technologies increases, the market is likely to witness significant growth; in the short term, majority of service-based revenues is likely to come from drug product related projects

     

    For more information, please visit https://www.rootsanalysis.com/reports/view_document/continuous-manufacturing/308.html

     

    Table of Contents

     

    TABLE OF CONTENTS

     

    1. PREFACE

    1.1.       Scope of the Report

    1.2.       Research Methodology

    1.3.       Chapter Outlines

     

    1. EXECUTIVE SUMMARY

     

    1. INTRODUCTION

    3.1.       Chapter Overview

    3.2.       Historical Evolution of Continuous Manufacturing

    3.3.       Continuous Manufacturing in the Pharmaceutical Industry

    3.3.1.    Regulatory Landscape

    3.3.2.    Early Adopters of Continuous Manufacturing

    3.3.3.    Anticipated Shift to Continuous Manufacturing

    3.3.4.    Advantages of Continuous Manufacturing

    3.3.5.    Key Challenges Associated with Continuous Manufacturing

    3.3.6.    Future Perspectives

     

    1. MARKET LANDSCAPE

    4.1.       Chapter Overview

    4.2.       Companies with Expertise in Continuous Manufacturing: Overall Market Landscape

    4.2.1.    Analysis by Year of Establishment

    4.2.2.    Analysis by Company Size

    4.2.3.    Analysis by Purpose of Manufacturing

    4.2.4.    Analysis by Scale of Operation

    4.2.5.    Analysis by Location of Headquarters

    4.2.6.    Analysis by Location of Continuous Manufacturing Facilities

    4.2.7.    Analysis by Type of Drug Molecule

    4.2.8.    Analysis by Type of Continuous Manufacturing Related Service

    4.2.9.    Analysis by Type of Dosage Form

    4.2.10.  Heat Map: Analysis by Company Size and Location of Headquarters

    4.2.11.  Information on Production Capacity

    4.2.12.  Logo Landscape: Analysis by Year of Establishment and Company Size 

    4.2.13.  Grid Representation: Analysis by Scale of Operation, Type of Continuous Manufacturing Related Service and Type of Dosage Form

    4.2.14.  Geographical Map: Analysis by Location of Continuous Manufacturing Facilities and Type of Drug Molecule

     

    1. COMPANIES WITH EXPERTISE IN CONTINUOUS MANUFACTURING IN NORTH AMERICA: PROFILES

    5.1.       Chapter Overview

    5.2.       AbbVie Contract Manufacturing

    5.2.1.    Company Overview

    5.2.2.    Service Portfolio

    5.2.3.    Continuous Manufacturing Capabilities and Facilities

    5.2.4.    Recent Developments and Future Outlook

     

    5.3.       Cambrex

    5.3.1.    Company Overview

    5.3.2.    Service Portfolio

    5.3.3.    Continuous Manufacturing Capabilities and Facilities

    5.3.4.    Recent Developments and Future Outlook

     

    5.4.       Patheon

    5.4.1.    Company Overview

    5.4.2.    Service Portfolio

    5.4.3.    Continuous Manufacturing Capabilities and Facilities

    5.4.4.    Recent Developments and Future Outlook

     

    5.5.       SK biotek

    5.5.1.    Company Overview

    5.5.2.    Service Portfolio

    5.5.3.    Continuous Manufacturing Capabilities and Facilities

    5.5.4.    Recent Developments and Future Outlook

     

    1. COMPANIES WITH EXPERTISE IN CONTINUOUS MANUFACTURING IN EUROPE: PROFILES

    6.1.       Chapter Overview

    6.2.       Ajinomoto Bio-Pharma Services

    6.2.1.    Company Overview

    6.2.2.    Service Portfolio

    6.2.3.    Continuous Manufacturing Capabilities and Facilities

    6.2.4.    Recent Developments and Future Outlook

     

    6.3.       Almac

    6.3.1.    Company Overview

    6.3.2.    Service Portfolio

    6.3.3.    Continuous Manufacturing Capabilities and Facilities

    6.3.4.    Recent Developments and Future Outlook

     

    6.4.       Boehringer Ingelheim BioXcellence™

    6.4.1.    Company Overview

    6.4.2.    Service Portfolio

    6.4.3.    Continuous Manufacturing Capabilities and Facilities

    6.4.4.    Recent Developments and Future Outlook

     

    6.5.       CordonPharma

    6.5.1.    Company Overview

    6.5.2.    Service Portfolio

    6.5.3.    Continuous Manufacturing Capabilities and Facilities

    6.5.4.    Recent Developments and Future Outlook

     

    6.6.       Hovione

    6.6.1.    Company Overview

    6.6.2.    Service Portfolio

    6.6.3.    Continuous Manufacturing Capabilities and Facilities

    6.6.4.    Recent Developments and Future Outlook

     

    6.7.       Lonza

    6.7.1.    Company Overview

    6.7.2.    Service Portfolio

    6.7.3.    Continuous Manufacturing Capabilities and Facilities

    6.7.4.    Recent Developments and Future Outlook

     

    1. COMPANIES WITH EXPERTISE IN CONTINUOUS MANUFACTURING IN ASIA-PACIFIC: PROFILES

    7.1.       Chapter Overview

    7.2.       Kaneka

    7.2.1.    Company Overview

    7.2.2.    Service Portfolio

    7.2.3.    Continuous Manufacturing Capabilities and Facilities

    7.2.4.    Recent Developments and Future Outlook     

     

    7.3.       WuXi AppTec

    7.3.1.    Company Overview

    7.3.2.    Service Portfolio

    7.3.3.    Continuous Manufacturing Capabilities and Facilities

    7.3.4.    Recent Developments and Future Outlook                 

     

    1. RECENT PARTNERSHIPS AND COLLABORATIONS

    8.1.       Chapter Overview

    8.2.       Partnership Models

    8.3.       List of Partnerships and Collaborations

    8.3.1.    Analysis by Year of Partnership

    8.3.2.    Analysis by Type of Partnership

    8.3.3.    Analysis by Scale of Operation

    8.3.4.    Analysis by Type of Drug Molecule

    8.3.5.    Analysis by Type of Continuous Manufacturing Related Service

    8.3.6.    Analysis by Type of Dosage Form

    8.3.7.    Most Active Players: Analysis by Number of Partnerships

     

    8.3.8.    Regional Analysis

    8.3.8.1. Intercontinental and Intracontinental Agreements

     

    1. RECENT EXPANSIONS

    9.1.       Chapter Overview

    9.2.       Recent Expansions

    9.2.1.    Analysis by Year of Expansion

    9.2.2.    Analysis by Type of Expansion

    9.2.3.    Analysis by Expanded Scale of Expansion

    9.2.4.    Analysis by Type of Drug Molecule

    9.2.5.    Analysis by Type of Continuous Manufacturing Related Service

    9.2.6.    Analysis by Type of Dosage Form

    9.2.7.    Most Active Players: Analysis by Number of Expansions

     

    9.2.8.    Regional Analysis

    9.2.8.1. Analysis by Location of Expansion Project

     

    1. CAPACITY ANALYSIS

    10.1.     Chapter Overview

    10.2.     Assumptions and Methodology

    10.3.     Global, Continuous Manufacturing Capacity for Small Molecule APIs

    10.3.1.  Analysis by Company Size

    10.3.2. Analysis by Purpose of Manufacturing

    10.3.3.  Analysis by Scale of Operation

    10.3.4.  Analysis by Location of Headquarters

    10.3.4.  Analysis by Location of Continuous Manufacturing Facilities

     

    10.4.     Global, Continuous Manufacturing Capacity for Small Molecule End Products

    10.4.1.  Analysis by Company Size

    10.4.2. Analysis by Purpose of Manufacturing

    10.4.3.  Analysis by Scale of Operation

    10.4.4.  Analysis by Location of Headquarters

    10.4.5.  Analysis by Location of Continuous Manufacturing Facilities

     

    10.5.     Global, Continuous Manufacturing Capacity for Biologic

    10.5.1.  Analysis by Company Size

    10.5.2. Analysis by Purpose of Manufacturing

    10.5.3.  Analysis by Scale of Operation

    10.5.4.  Analysis by Location of Headquarters

    10.5.5.  Analysis by Location of Continuous Manufacturing Facilities

     

    1. ACADEMIC GRANT ANALYSIS

    11.1.     Chapter Overview

    11.2.     Scope and Methodology

    11.3.     Continuous Manufacturing: List of Academic Grants

    11.3.1.  Analysis by Number of Grants

    11.3.2.  Analysis by Activity Code

    11.3.3.  Analysis by Grant Amount

    11.3.4.  Analysis by Focus Area

    11.3.5.  Analysis by Support Period

    11.3.6   Popular Recipient Organizations: Analysis by Number of Grants

    11.3.7   Analysis by Type of Recipient Organization

    11.3.8.  Analysis by Funding Institute Centre

    11.3.9.  Analysis by Funding Mechanism

    11.3.10. Prominent Program Officers: Analysis by Number of Grants

     

    1. PATENT ANALYSIS

    12.1.     Chapter Overview

    12.2.     Scope and Methodology

    12.3.     Continuous Manufacturing: Patent Analysis

    12.3.1.  Analysis by Publication Year

    12.3.2.  Analysis by Geography

    12.3.3.  Analysis by CPC Symbols

    12.3.4.  Emerging Focus Areas

    12.3.5.  Analysis by Type of Applicant

    12.3.6.  Leading Players: Analysis by Number of Patents

    12.3.7.  Continuous Manufacturing: Three-Dimensional Bubble Analysis

    12.3.8.  Continuous Manufacturing: Patent Valuation Analysis

    12.3.8.1. Leading Patents: Information by Number of Citations

     

    1. INITIATIVES OF COMPANIES WITH IN-HOUSE CONTINUOUS MANUFACTURING CAPABILITIES

    13.1.     Chapter Overview

    13.2.     Continuous Manufacturing Initiatives of Leading Companies

    13.2.1.  AbbVie

    13.2.1.1. Partnered Initiatives

    13.2.1.2 In-House Initiatives

     

    13.2.2.  Amgen

    13.2.2.1. Partnered Initiatives

    13.2.2.2. In-House Initiatives

     

    13.2.3.  Bristol-Myers Squibb

    13.2.3.1. Partnered Initiatives

    13.2.3.2. In-House Initiatives

     

    13.2.4.  GlaxoSmithKline

    13.2.4.1. Partnered Initiatives

    13.2.4.2. In-House Initiatives

     

    13.2.5.  Merck

    13.2.5.1. Partnered Initiatives

    13.2.5.2. In-House Initiatives

     

    13.2.6.  Novartis

    13.2.6.1. Partnered Initiatives

    13.2.6.2. In-House Initiatives

     

    13.2.7.  Pfizer

    13.2.7.1. Partnered Initiatives

    13.2.7.2. In-House Initiatives

     

    13.2.8.  Roche

    13.2.8.1. Partnered Initiatives

    13.2.8.2. In-House Initiatives

    13.2.9.  Sanofi

    13.2.9.1. Partnered Initiatives

    13.2.9.2. In-House Initiatives

     

    1. CASE STUDY: MODULAR FACILITIES IN PHARMACEUTICAL / BIOTECHNOLOGY INDUSTRY

    14.1.     Chapter Overview

    14.2.     Historical Background

    14.3.     Concept of Modularization

    14.3.1.  Types of Modules

    14.3.2.  Modular Construction Process

     

    14.4.     Modular Construction in the Pharmaceutical Industry

    14.4.1.  Advantages of Modular Construction in the Pharmaceutical Industry

     

    14.5.     Modular Facility Manufacturers

    14.5.1.  Distribution by Industry Served

    14.5.2.  Distribution by Geography

    14.5.3.  Modular Projects Executed / Undertaken

     

    14.6.     Modular Pharmaceutical Cleanrooms

    14.6.1.  Cleanroom Classification and Current Standards

    14.6.2.  Advantages of Modular Cleanrooms

    14.6.3.  Regulations and Standards Concerning Modular Cleanroom Construction

     

    14.7.     Modular Cleanroom Providers

    14.7.1.  Distribution by Industry Served

    14.7.2.  Distribution by Geography

    14.7.3.  Type of Modular Cleanrooms Offered

     

    1. CASE STUDY: TECHNOLOGY AND EQUIPMENT PROVIDERS

    15.1.     Chapter Overview

    15.2.     Types of Continuous Manufacturing Technologies

    15.3.     Equipment and Technologies for Continuous Manufacturing Small Molecules and Biologics

    15.3.1.  Continuous Blending and Mixing Equipment

    15.3.2.  Continuous Granulating Equipment

    15.3.3.  Continuous Drying Equipment

    15.3.4.  Continuous Compression Equipment

    15.3.5.  Continuous Coating Equipment

    15.3.6.  Continuous Filtration, Continuous Distillation and Continuous Centrifugation Equipment

    15.3.7.  Continuous Chromatography Equipment

    15.3.8.  Continuous Reactors / Bioreactors

    15.3.9.  Full Line Continuous Platforms

    15.3.10. Process Analytical Technologies

    15.3.11. Other Technologies

    15.4.     Logo Landscape: Analysis of Technology Providers by Number and Type of Equipment

     

    1. CASE STUDY: ROADMAP FOR THE ADOPTION OF CONTINUOUS MANUFACTURING PROCESSES

    16.1.     Chapter Overview

    16.2.     Key Strategies for the Adoption of Continuous Manufacturing Processes

    16.2. 1. Phase I: Process Development and Implementation

    16.2. 2. Phase II: Equipment / Technology Development and Installation

    16.2. 3. Phase III: Facility / Plant Development and Establishment

    16.2. 4. Phase IV: Product Development and Manufacturing

     

    1. MARKET FORECAST AND OPPORTUNITY ANALYSIS

    17.1.     Chapter Overview

    17.2.     Forecast Methodology and Key Assumptions

    17.3.     Overall, Continuous Manufacturing Market, 2020-2030

    17.3.1.  Continuous Manufacturing Market: Distribution by Purpose of Manufacturing, 2020-2030

    17.3.2.  Continuous Manufacturing Market: Distribution by Scale of Operation, 2020-2030

    17.3.3.  Continuous Manufacturing Market: Distribution by Type of Drug Molecule, 2020-2030

    17.3.4.  Continuous Manufacturing Market: Distribution by Type of Continuous Manufacturing Related Service, 2020-2030

    17.3.5.  Continuous Manufacturing Market: Distribution by Type of Dosage Form, 2020-2030

    17.3.6.  Continuous Manufacturing Market: Distribution by Key Geographical Regions, 2020-2030

     

    17.4.     Continuous Manufacturing Market for Small Molecule, 2020-2030

    17.4.1.  Distribution by Purpose of Manufacturing, 2020-2030

    17.4.2.  Distribution by Scale of Operation, 2020-2030

    17.4.3.  Distribution by Type of Continuous Manufacturing Related Service, 2020-2030

    17.4.4.  Distribution by Key Geographical Regions, 2020-2030

     

    17.5.     Continuous Manufacturing Market for Biologic, 2020-2030

    17.5.1.  Distribution by Purpose of Manufacturing, 2020-2030

    17.5.2.  Distribution by Scale of Operation, 2020-2030

    17.5.3.  Distribution by Type of Continuous Manufacturing Related Service, 2020-2030

    17.5.4.  Distribution by Key Geographical Regions, 2020-2030

     

    1. CONCLUSION

    18.1.     Chapter Overview

    18.2.     Key Takeaways

     

    1. EXECUTIVE INSIGHTS

    19.1.     Chapter Overview

    19.2.     Zaiput Flow Technologies

    19.2.1.  Company Snapshot

    19.2.2.  Interview Transcript: Andrea Adamo, Founder and Chief Executive Officer

     

    19.3.     CONTINUUS Pharmaceuticals

    19.3.1.  Company Snapshot

    19.3.2.  Interview Transcript: Bayan Takizawa, Co-Founder and Chief Business Officer

     

    19.4.     Snapdragon Chemistry

    19.4.1.  Company Snapshot

    19.4.2.  Interview Transcript: Eric Fang, Chief Scientific Officer

     

    19.5.     Enzene Biosciences

    19.5.1.  Company Snapshot

    19.5.2.  Interview Transcript: Himanshu Gadgil, Director and Chief Scientific Officer

     

    19.6.     Pfizer

    19.6.1.  Company Snapshot

    19.6.2.  Interview Transcript: Nick Thomson, Senior Director Chemical Research and Development

    19.7.     University of Strathclyde

    19.7.1.  Company Snapshot

    19.7.2.  Interview Transcript: Ian Houson, Technical Project Manager

     

     

    1. APPENDIX 1: TABULATED DATA

     

    1. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

     

    Contact Details

    Gaurav Chaudhary

    +1 (415) 800 3415

    gaurav.chaudhary@rootsanalysis.com


  • The continuous manufacturing market is estimated to be worth around USD 2 billion in 2030

    Recent advances in the manufacturing technologies have prompted pharmaceutical companies to consider shifting from the traditional multi-step, batch manufacturing processes to faster, and relatively more efficient continuous manufacturing

     

    Roots Analysis is pleased to announce the publication of its recent study, titled, “Continuous Manufacturing Market (Small Molecules and Biologics), 2020 – 2030.”

     

    The report features an extensive study of the current market landscape and future opportunities for companies with capabilities in continuous manufacturing (both innovator companies with in-house expertise and contract manufacturers). It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes:

    • A detailed assessment of the overall landscape of companies with capabilities for continuous manufacturing
    • Elaborate profiles of some of the key contract manufacturers active in the pharmaceutical and biopharmaceutical continuous manufacturing market
    • An analysis of the various partnerships related to continuous manufacturing, which have been established since 2013
    • An analysis of the expansions related to continuous manufacturing, which have been established since 2013
    • An estimate of the global, continuous manufacturing capacity, based on the capacities of various industry stakeholders (as available on their respective company websites).
    • A study of the various grants that have been awarded to research institutes engaged in projects related to continuous manufacturing, between 2014 and 2019
    • An in-depth analysis of the various patents that have been filed / granted related to continuous manufacturing till 2019
    • Initiatives taken by the leading pharmaceutical companies (in terms of revenues), covering both partnered as well as in-house projects.
    • A review of the companies offering modular facilities / modular cleanrooms
    • A case study of the companies offering technologies / equipment
    • A case study on the roadmap for the adoption of continuous manufacturing technique
    • A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
    • Purpose of Manufacturing
    • In-House
    • Contract service
    • Scale of Operation
    • Commercial
    • Preclinical / Clinical
    • Type of Continuous Manufacturing related Service
    • API Manufacturing
    • End Product manufacturing
    • Type of Drug Molecule
    • Biologic
    • Small Molecule
    • Type of dosage form
    • Solid
    • Liquid
    • Key Geographical Regions
    • North America
    • Europe
    • Asia Pacific

     

    • Transcripts of interviews held with the following senior level representatives of stakeholder companies
    • Andrea Adamo, Founder and Chief Executive Officer, Zaiput Flow technologies
    • Bayan Takizawa, Co-Founder and Chief Business Officer, CONTINUUS Pharmaceuticals
    • Nick Thomson, Senior Director Chemical Research and Development, Pfizer
    • Himanshu Gadgil, Director and Chief Scientific Officer, Enzene Biosciences
    • Eric Fang, Chief Scientific Officer, Snapdragon Chemistry)
    • Ian Houson, Technical Project Manager, Continuous Manufacturing and Crystallization, University of Strathclyde

     

    Key companies covered in the report

    • AbbVie Contract Manufacturing
    • Ajinomoto Bio-Pharma Services
    • Almac
    • Boehringer Ingelheim BioXcellence
    • Cambrex
    • CordonPharma
    • Hovione
    • Kaneka
    • Lonza
    • Patheon
    • SK biotek
    • WuXi AppTec

     

    For more information please click on the following link:

    https://www.rootsanalysis.com/reports/view_document/continuous-manufacturing/308.html

     

    Other Offerings

    1. Pharmaceutical Contract Manufacturing Market (2nd Edition), 2018-2028
    2. Biopharma Contract Manufacturing Market (3rd Edition), 2019 - 2030
    3. China Pharmaceutical Contract Manufacturing Services Market, 2020-2030
    4. China Biopharmaceutical Contract Manufacturing Market, 2020 - 2030

     

    About Roots Analysis

    Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

     

    Contact Information

    Roots Analysis Private Limited

    Gaurav Chaudhary

    +1 (415) 800 3415

    gaurav.chaudhary@rootsanalysis.com

     

     


  • The continuous manufacturing market is estimated to be worth around USD 2 billion in 2030

    Recent advances in the manufacturing technologies have prompted pharmaceutical companies to consider shifting from the traditional multi-step, batch manufacturing processes to faster, and relatively more efficient continuous manufacturing

     

    Roots Analysis is pleased to announce the publication of its recent study, titled, “Continuous Manufacturing Market (Small Molecules and Biologics), 2020 – 2030.”

     

    The report features an extensive study of the current market landscape and future opportunities for companies with capabilities in continuous manufacturing (both innovator companies with in-house expertise and contract manufacturers). It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes:

    • A detailed assessment of the overall landscape of companies with capabilities for continuous manufacturing
    • Elaborate profiles of some of the key contract manufacturers active in the pharmaceutical and biopharmaceutical continuous manufacturing market
    • An analysis of the various partnerships related to continuous manufacturing, which have been established since 2013
    • An analysis of the expansions related to continuous manufacturing, which have been established since 2013
    • An estimate of the global, continuous manufacturing capacity, based on the capacities of various industry stakeholders (as available on their respective company websites).
    • A study of the various grants that have been awarded to research institutes engaged in projects related to continuous manufacturing, between 2014 and 2019
    • An in-depth analysis of the various patents that have been filed / granted related to continuous manufacturing till 2019
    • Initiatives taken by the leading pharmaceutical companies (in terms of revenues), covering both partnered as well as in-house projects.
    • A review of the companies offering modular facilities / modular cleanrooms
    • A case study of the companies offering technologies / equipment
    • A case study on the roadmap for the adoption of continuous manufacturing technique
    • A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
    • Purpose of Manufacturing
    • In-House
    • Contract service
    • Scale of Operation
    • Commercial
    • Preclinical / Clinical
    • Type of Continuous Manufacturing related Service
    • API Manufacturing
    • End Product manufacturing
    • Type of Drug Molecule
    • Biologic
    • Small Molecule
    • Type of dosage form
    • Solid
    • Liquid
    • Key Geographical Regions
    • North America
    • Europe
    • Asia Pacific

     

    • Transcripts of interviews held with the following senior level representatives of stakeholder companies
    • Andrea Adamo, Founder and Chief Executive Officer, Zaiput Flow technologies
    • Bayan Takizawa, Co-Founder and Chief Business Officer, CONTINUUS Pharmaceuticals
    • Nick Thomson, Senior Director Chemical Research and Development, Pfizer
    • Himanshu Gadgil, Director and Chief Scientific Officer, Enzene Biosciences
    • Eric Fang, Chief Scientific Officer, Snapdragon Chemistry)
    • Ian Houson, Technical Project Manager, Continuous Manufacturing and Crystallization, University of Strathclyde

     

    Key companies covered in the report

    • AbbVie Contract Manufacturing
    • Ajinomoto Bio-Pharma Services
    • Almac
    • Boehringer Ingelheim BioXcellence
    • Cambrex
    • CordonPharma
    • Hovione
    • Kaneka
    • Lonza
    • Patheon
    • SK biotek
    • WuXi AppTec

     

    For more information please click on the following link:

    https://www.rootsanalysis.com/reports/view_document/continuous-manufacturing/308.html

     

    Other Offerings

    1. Pharmaceutical Contract Manufacturing Market (2nd Edition), 2018-2028
    2. Biopharma Contract Manufacturing Market (3rd Edition), 2019 - 2030
    3. China Pharmaceutical Contract Manufacturing Services Market, 2020-2030
    4. China Biopharmaceutical Contract Manufacturing Market, 2020 - 2030

     

    About Roots Analysis

    Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

     

    Contact Information

    Roots Analysis Private Limited

    Gaurav Chaudhary

    +1 (415) 800 3415

    gaurav.chaudhary@rootsanalysis.com

     

     


  • The continuous manufacturing market is estimated to be worth around USD 2 billion in 2030

    Recent advances in the manufacturing technologies have prompted pharmaceutical companies to consider shifting from the traditional multi-step, batch manufacturing processes to faster, and relatively more efficient continuous manufacturing

     

    Roots Analysis is pleased to announce the publication of its recent study, titled, “Continuous Manufacturing Market (Small Molecules and Biologics), 2020 – 2030.”

     

    The report features an extensive study of the current market landscape and future opportunities for companies with capabilities in continuous manufacturing (both innovator companies with in-house expertise and contract manufacturers). It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes:

    • A detailed assessment of the overall landscape of companies with capabilities for continuous manufacturing
    • Elaborate profiles of some of the key contract manufacturers active in the pharmaceutical and biopharmaceutical continuous manufacturing market
    • An analysis of the various partnerships related to continuous manufacturing, which have been established since 2013
    • An analysis of the expansions related to continuous manufacturing, which have been established since 2013
    • An estimate of the global, continuous manufacturing capacity, based on the capacities of various industry stakeholders (as available on their respective company websites).
    • A study of the various grants that have been awarded to research institutes engaged in projects related to continuous manufacturing, between 2014 and 2019
    • An in-depth analysis of the various patents that have been filed / granted related to continuous manufacturing till 2019
    • Initiatives taken by the leading pharmaceutical companies (in terms of revenues), covering both partnered as well as in-house projects.
    • A review of the companies offering modular facilities / modular cleanrooms
    • A case study of the companies offering technologies / equipment
    • A case study on the roadmap for the adoption of continuous manufacturing technique
    • A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
    • Purpose of Manufacturing
    • In-House
    • Contract service
    • Scale of Operation
    • Commercial
    • Preclinical / Clinical
    • Type of Continuous Manufacturing related Service
    • API Manufacturing
    • End Product manufacturing
    • Type of Drug Molecule
    • Biologic
    • Small Molecule
    • Type of dosage form
    • Solid
    • Liquid
    • Key Geographical Regions
    • North America
    • Europe
    • Asia Pacific

     

    • Transcripts of interviews held with the following senior level representatives of stakeholder companies
    • Andrea Adamo, Founder and Chief Executive Officer, Zaiput Flow technologies
    • Bayan Takizawa, Co-Founder and Chief Business Officer, CONTINUUS Pharmaceuticals
    • Nick Thomson, Senior Director Chemical Research and Development, Pfizer
    • Himanshu Gadgil, Director and Chief Scientific Officer, Enzene Biosciences
    • Eric Fang, Chief Scientific Officer, Snapdragon Chemistry)
    • Ian Houson, Technical Project Manager, Continuous Manufacturing and Crystallization, University of Strathclyde

     

    Key companies covered in the report

    • AbbVie Contract Manufacturing
    • Ajinomoto Bio-Pharma Services
    • Almac
    • Boehringer Ingelheim BioXcellence
    • Cambrex
    • CordonPharma
    • Hovione
    • Kaneka
    • Lonza
    • Patheon
    • SK biotek
    • WuXi AppTec

     

    For more information please click on the following link:

    https://www.rootsanalysis.com/reports/view_document/continuous-manufacturing/308.html

     

    Other Offerings

    1. Pharmaceutical Contract Manufacturing Market (2nd Edition), 2018-2028
    2. Biopharma Contract Manufacturing Market (3rd Edition), 2019 - 2030
    3. China Pharmaceutical Contract Manufacturing Services Market, 2020-2030
    4. China Biopharmaceutical Contract Manufacturing Market, 2020 - 2030

     

    About Roots Analysis

    Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

     

    Contact Information

    Roots Analysis Private Limited

    Gaurav Chaudhary

    +1 (415) 800 3415

    gaurav.chaudhary@rootsanalysis.com

     

     


  • The “Fragment-based Drug Discovery Market: Library and Service Providers, 2020-2030

    Key Inclusions

    • A detailed review of the overall landscape of fragment-based drug discovery library and service providers along with the information on type of product (library and technology), type of service offered (fragment screening and fragment optimization), type of technique used (X-ray crystallography, nuclear magnetic resonance, surface plasmon resonance, and other screening techniques), other services offered (target identification / validation, hit identification, hit-to-lead / lead generation, lead optimization), and end user (industry, academia, and contract research organizations).
    • Elaborate profiles of the companies providing libraries and services for fragment-based drug discovery (shortlisted on the basis of the service portfolio and number of fragment screening techniques offered). Each profile features a brief overview of the company, its financial information (if available), fragment-based library and service portfolio, information on other drug discovery services, recent developments and an informed future outlook.
    • An analysis of the partnerships that have been established in the recent past, covering R&D collaborations, mergers and acquisitions, product development and commercialization agreements, commercialization agreements, distribution and supply agreements, product integration agreements, service agreements, and other relevant types of deals.
    • A detailed analysis on acquisition targets, taking into consideration the historical trend of the activity of the companies that have acquired other firms since 2015, and offering a means for other industry stakeholders to identify potential acquisition targets.
    • An insightful competitiveness analysis of fragment-based drug discovery library and service providers, based on supplier power (based on the years of experience of service provider) and key specifications, such as number of fragment libraries and number of screening techniques.
    • An analysis highlighting the cost saving potential associated with the use of fragment-based drug discovery approach.
    • Informed estimates of the existing market size and the future opportunity for fragment-based drug discovery library and services, over the next decade. Based on multiple parameters, such as annual number of drug discovery projects, outsourcing profile, and adoption of fragment-based drug discovery approach, we have provided informed estimates on the evolution of the market for the period 2020-2030.

     

    The report features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:

    • Type of Screening Technique Used
    • X-ray Crystallography
    • Nuclear Magnetic Resonance
    • Surface Plasmon Resonance
    • Other Screening Techniques

     

    • Type of Service Offered
    • Library Screening
    • Fragment Screening
    • Fragment Optimization

     

    • End User
    • Industry Players
    • Non-Industry Players

     

    • Key geographical regions

    Press Release: Variation 4 (Format 5)

     

    • North America (US and Canada)
    • Europe (UK, France, Germany, Spain, Italy, and rest of Europe)
    • Asia-Pacific (China, Japan, India, and rest of Asia-Pacific / rest of the world)

     

    The report also features inputs from eminent industry stakeholders, according to whom the fragment-based approach significantly simplifies the drug discovery process. The report includes detailed transcripts of discussions held with the following experts:

     

    To request sample pages, please visit this link             

                                                                                                                   

    Key Questions Answered

    • Who are the leading players in the fragment-based drug discovery library and services market?
    • What are the key biophysical techniques used by service providers for screening fragment libraries and lead optimization?
    • Which types of partnership models are commonly adopted by stakeholders in this domain?
    • What is the likely cost-saving opportunity associated with the use of fragment-based drug discovery?
    • How is the current and future market opportunity likely to be distributed across key market segments?

     

    You may also be interested in the following titles:

    1. DNA-Encoded Libraries: Platforms and Services Market
    2. Antibody Discovery: Services and Platforms Market (2nd Edition), 2018-2028
    3. In Silico / Computer-Aided Drug Discovery Services Market: Focus on Large Molecules (Antibodies, Proteins, Peptides, Nucleic Acid, Gene Therapy and Vectors), 2020-2030 (Including Structure Based Drug Discovery, Fragment Based Drug Discovery, Ligand Based Drug Discovery, Target Based Drug Discovery, Interface Based Drug Discovery Approaches)

     

    Contact Us:

    Gaurav Chaudhary

    +1 (415) 800 3415

    +44 (122) 391 1091

    Gaurav.Chaudhary@rootsanalysis.com


  • Over 85 firms are involved in providing fragment-based drug discovery-related services

    According to experts in this field, fragment-based drug discovery solutions have facilitated the identification of viable pharmacological leads against otherwise hard to target biomolecules. In fact, many service provider companies are offering fragment libraries and support to the medical research community in order to develop an appropriate intervention to treat the illness caused by the SARS-CoV-2 virus.

     

    To order this 170+ page report, which features 55+ figures and 80+ tables, please visit this link

     

    The USD 1.6 billion (by 2030) financial opportunity within the fragment-based drug discovery market has been analyzed across the following segments:

    • Type of Screening Technique Used
    • X-ray Crystallography
    • Nuclear Magnetic Resonance
    • Surface Plasmon Resonance
    • Other Screening Techniques

     

    • Type of Service Offered
    • Library Screening
    • Fragment Screening
    • Fragment Optimization

     

    • End User
    • Industry Players
    • Non-Industry Players

     

    • Key geographical regions
    • North America (US and Canada)
    • Europe (UK, France, Germany, Spain, Italy, and rest of Europe)
    • Asia-Pacific (China, Japan, India, and rest of Asia-Pacific / rest of the world)

     

    The Fragment-based Drug Discovery Market: Library and Service Providers, 2020-2030 report features the following companies, which we identified to be key players in this domain:

    • 2bind
    • Charles River Laboratories
    • ChemAxon
    • ComInnex
    • Creative Biolabs
    • Creative Biostructure
    • CRELUX
    • Domainex
    • Evotec
    • Red Glead Discovery
    • SARomics Biostructures
    • Shanghai ChemPartner
    • Sygnature Discovery
    • Vernalis Research

     

    Table of Contents

     

     

     

    Press Release: Variation 3 (Format 4)

     

    1. Preface

      2. Executive Summary

    2. Introduction

    3. Current Market Landscape

    4. Company Profiles: Fragment-based Drug Discovery Library and Service Providers

    5. Partnerships and Collaborations

    6. Key Acquisition Targets

    7. Company Competitiveness Analysis

    8. Cost Saving Analysis

    9. Market Forecast and Opportunity Analysis

    10. Executive Insights

     

    1. Concluding Remarks

     

    1. Appendix 1: Tabulated Data

     

    1. Appendix 2: List of Companies and Organizations

     

    To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/fragment-based-drug-discovery/309.html

     

    Contact Details

    Gaurav Chaudhary

    +1 (415) 800 3415

    Gaurav.Chaudhary@rootsanalysis.com


connect